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GENOME-WIDE ASSOCIATION STUDIES AT THE INTERFACE OF  
ALZHEIMER’S DISEASE AND EPIDEMIOLOGICALLY RELATED DISORDERS 
 
 
Genome-wide association studies (GWAS)s provide an unbiased means of 
exploring the landscape of complex genetic disease.  As such, these studies have 
identified genetic variants that are robustly associated with a multitude of conditions.  
I hypothesize that these genetic variants serve as excellent tools for evaluation of 
the genetic interface between epidemiologically related conditions.  Herein, I test the 
association between SNPs associated with either (i) plasma lipids, (ii) rheumatoid 
arthritis (RA) or (iii) diabetes mellitus (DM) and late-onset Alzheimer’s disease (AD) 
to identify shared genetic variants.  Regarding the most significantly AD-associated 
variants, I have also attempted to elucidate their molecular function. 
Only cholesterol-associated SNPs, as a group, are significantly associated 
with AD.  This association remains after excluding APOE SNPs and suggests that 
peripheral and or central cholesterol metabolism contribute to AD risk.  The general 
lack of association between RA-associated SNPs and AD is also significant in that 
these data challenge the hypothesis that genetic variants that increase risk of RA 
confer protection against AD.  Functional studies of variants exhibiting novel 
associations with AD reveal that the lipid-associated SNP rs3846662 modulates 
HMGCR exon 13 splicing differentially in different cell types.  Although less clear, 
trends were also observed between the RA-associated rs2837960 and the 
expression of several BACE2 isoforms, and between the DM-associated rs7804356 
and expression of a rare SKAP2 isoform, respectively. 
 In conclusion, the overlap of lipid-, RA- or DM-associated SNPs with AD is 
modest but in several instances significant.  Continued analysis of the interface 
between GWAS of separate conditions will likely facilitate novel associations missed 
by conventional GWAS.  Furthermore, the identification of functional variants 
associated with multiple conditions should provide insight into novel mechanisms of 
disease and may lead to the identification of new therapeutic targets in an era of 
personalized genomic medicine. 
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CHAPTER ONE 
 
INTRODUCTION TO THE GENOMIC ERA AND  
GENOME-WIDE ASSOCIATION STUDIES 
 
 
Sequencing of the Genome 
 
 Coincident with the turn of the millennium, a draft of the Homo sapiens 
genome sequence was released to the public [1, 2].  There was promise that within 
the genome we would find the blueprints for human development, function, repair, 
aging and death.  These promises have been fulfilled to some extent but have likely 
raised more questions than answers.  Furthermore, this initial “blueprint” failed to 
reflect the complexity and variation that make our individual genomes unique.  As a 
consequence, researchers have moved toward analyzing genomic variation in hopes 
of understanding why certain individuals are predisposed to disease while others go 
about their lives unscathed despite risky behaviors.  In parallel, a collaborative effort 
on the part of scientists, clinicians, lawyers and the community at-large has been 
initiated to safeguard individuals and direct the usage of genomic data with the 
promise of bettering the health of mankind in what has become the genomic era [3].  
In light of rapidly developing sequencing technologies, the question of how to 
analyze the massive amount of variation within the genome remains.  My work 
entails a novel approach to such analysis – namely the analysis of variants that lie at 
the interface of multiple diseases or traits. 
 
Composition of the Genome 
 
The human genome is thought to contain some ~22,000 genes, ie. discrete 
segments of DNA that are transcribed into an RNA intermediate and ultimately direct 
the synthesis of structural and enzymatic proteins [4].  The general positions of 
these genes within the genome are referred to as loci (singular, locus).  To 
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oversimplify matters, each locus is surrounded by or embedded with DNA sequence 
dictating when, where and how each gene should be expressed per its interaction 
with DNA-regulatory factors.  Either independently, or in concert with one another, 
the sum of these loci interact with the environment to determine an organism’s 
phenotype, or observable set characteristics.  Furthermore, the passage of genes 
from parent to offspring facilitates a heritable means of passing on phenotypes from 
one generation to the next. 
 
A Brief history of the Chemical Nature of the Genome 
 
Deoxyrilbonucleic acid (DNA) is the principal biochemical component of the 
human genome.  DNA was initially characterized by physician-scientist Friedrich 
Miescher in 1869 while studying the chemical contents of the cell nucleus.  However, 
it was Phoebus Levene who first described the structure of the nucleotide, i.e. the 
individual building block of DNA, in 1915 [5].  Further work by Torbjörn Caspersson 
and Einar Hammersten in 1934 led to the discovery that individual nucleotides are 
linked together in sequence to form long polymers, which constitute the primary 
structure of DNA[6].  Evidence of the capacity of DNA to store information that could 
be passed on from one generation to the next was not documented until Oswald 
Avery and colleagues observed that DNA isolated from a pathogenic strain of 
Pneumococcus could transform a non-pathogenic strain into a virulent one [7]. 
In the year 1962 James D. Watson and Francis Crick, together with Maurice 
Wilkins, were awarded the Nobel prize for their 1953 work with the secondary, 
double-helix structure of DNA.  Building upon the observation of Erwin Chargaff that 
a given DNA sample contains roughly equal amounts of the nucleotides adenine (A) 
and thymine (T) and equal amounts of the nucleotides cytosine (C) and guanine (G), 
Watson and Crick described a potential mechanism for the pairing of A:T and G:C 
nucleotides in the DNA double helix [8-10].  Together with the work of Alfred 
Hershey and Martha Chase, this led to the hypothesis that DNA is the genetic 
material of the cell and that its primary sequence can be precisely copied and thus 
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transmitted from one generation to the next as a sort of instruction manual for the 
cell [11].  
 
Overview of Genetic Variation 
 
Assuming that a sort of chemical instruction manual could manifest from lining 
up every human base pair, each individual’s instruction manual would be slightly 
different.  Although Chargaff’s rule would still apply, the exact sequence of two 
genomes would differ.  These differences, or variations, are referred to as alleles.  
For example, the same base position may be occupied by an adenosine in one 
individual and a thymine in another individual (Francis Collins, director of the NIH, 
once wrote a very nice song about being “flummoxed” by this phenomenon to the 
tune of Del Shannon’s “Runaway”).  In this instance, the two nucleotides represent 
different alleles.  One allele is often more present in a given population, leading to 
the notion that the other allele is a mutation.  However, the term mutation can be 
misleading since the ancestral allele is not always the most frequent allele.  Thus, 
the term variation will be used in this text although the term mutation may also be 
acceptable in some cases. 
Human variation comes in many forms and is influenced by multiple forces.  
The genesis of this variation likely involves errors in DNA replication, DNA 
recombination, the insertion of viral genome components and/or the insertion and 
excision of mobile transposon elements.  The amount of variation in a breeding 
population often reflects the point of divergence from more ancestral populations.  
This is evident in the relatively small amount of variation among isolated Caucasian 
populations as compared to ancestral African populations [12]. 
The most common from of human variation is the single nucleotide 
polymorphism (SNP), which entails variation at a single base position.  These 
variants occur at a frequency of 1 per 1,000 base pairs and constitute 88% of the 
isolated variations in the genome [13].  The number of human SNPs identified 
currently exceeds 15 million and still growing [14].  Their high frequency throughout 
the genome has allowed for construction of haplotypes, or groups of co-inherited 
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alleles, based on linkage disequilibrium (LD) maps that reflect regions of the genome 
between recombination hotspots [15, 16].  Thus, the majority of human haplotypes 
can be surveyed by genotyping for approximately 1 million SNPs.  The small size of 
SNPs and the haplotypic nature of the genome facilitate high-throughput genotyping 
per array-based technology, ie. SNP-chips. 
It may seem as though SNP-chip technology, haplotypes and LD maps 
capture the majority of human variation but the truth is that less frequent, larger 
structural variations in the genome account for ~75% of variant bases [13].  These 
structural mutations include indels (insertions and deletions) as well as duplications, 
copy number variants and inversions.  The massiveness of these variants has been 
realized only recently thanks to advances in whole-genome sequencing technologies.  
Whole-genome sequencing has also enabled the detection of more rare SNPs, 
further expanding the repertoire of human variation. 
It is noteworthy that these variants, large and small, appear throughout the 
genome.  SNPs, for example, occur in coding as well as non-coding (intronic or 
intergenic) sequence.  The association of SNPs with various traits (discussed later in 
this chapter) has broadened our understanding of the regulatory nature of non-
coding sequence.  Generally speaking, variants nearly anywhere in the genome 
have the potential to affect gene regulation via cis (same chromosome) and trans 
(different chromosome) mechanisms.  The combined frequency of SNPs and size of 
structural variations suggests that regulation of the genome may be more complex 
than previously believed.  Furthermore, the cumulative effect of these variations 
likely plays a significant role in human health and disease. 
 
The Heritability of Traits 
  
Mendelian Inheritance 
 
 Nearly one hundred years before the discovery of DNA, the notion was born 
that an organism’s characteristics were in part the result of a heritable, biological 
material.  It was the mid-nineteenth century when the Austrian monk Gregor Mendel 
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began experimenting with Pisum sativum hybrids at St Thomas’s Abbey in the 
Czech Republic.  Mendel’s objective was to understand in detail how certain hybrids 
could disappear and reappear across generations of breeding.  Thus, for eight years 
Mendel artificially fertilized and crossed his pea plants in an attempt to derive a set 
of laws that would govern how certain characteristics, or traits, could be passed to 
offspring.   
Traits such as the shape and color of the seed, the pea pods, the color of the 
flowers and the length of the stems were all observed across successive 
generations.  By following the transmission of these traits Mendel was able to 
statistically model the distribution of traits among progeny and conclude that different 
traits were inherited independently, thus forming the basis of Mendel’s Laws of 
Segregation and Independent Assortment.  Essentially, Mendel’s experiments 
revealed that unrelated traits could be attributed to different alleles, or variations of 
individual loci, which are passed on with patterned randomness to successive 
generations [17]. 
  
Qualitative vs. Quantitative Traits 
 
Mendel’s experiments were successful because the plant characteristics, or 
traits, he chose to study were mono-allelic and dichotomous, or qualitative.  Other 
traits, such as human height, are not discrete but rather are continuous and 
approximate normal distributions within different populations.  The study of 
continuous, or quantitative traits, across generations proved difficult since no clear 
pattern of inheritance existed for such traits.  The English population geneticist 
Ronald Fischer was among the first to show that quantitative traits would still be 
bound to Mendel’s laws of inheritance if such traits were influenced by multiple loci 
and were poly-allelic in nature [18].  Thus, by the early twentieth century the 
foundation had been laid for the study of both simple (ie. Mendelian) and complex 
(or continuous, poly-allelic) traits. 
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Genome-Wide Association Studies (GWAS) 
 
 Sequencing of the entire human genome has allowed for subsequent 
identification and cataloguing of human genetic variation [16, 19].  Resultantly, a 
map of human genome has been generated that consists of more than three million 
SNPs, the most common form of genetic variation.  This map can be simplified 
somewhat due to the occurrence of naturally delineated haplotypes, ie. groups of 
SNPs that are co-inherited.  Thus, a large portion of human genetic variation can be 
surveyed by genotyping for a limited number of SNPs that are representative of all 
human haplotypes.  This has led to he construction of genome-wide SNP arrays that 
provide a means to evaluate human genetic variation by simultaneously genotyping 
for approximately 1 million SNPs. 
 The methodology behind GWAS involves surveying individual human genetic 
variation, using high-throughput genome-wide SNP arrays, in thousands of 
individuals and testing for association between those variants and a given trait or 
condition.  Tests for association can be performed for both dichotomous variables 
(eg. presence or absence of disease) or for continuous variables (eg. height, blood 
pressure, circulating lipids) and often utilize logistic or linear regression models, 
respectively.  Regardless, GWAS rely on the underlying assumptions of the common 
variant, common disease hypothesis regarding inheritance patterns of complex 
diseases with a polygenic risk component [20-22].  In other words, for GWAS to be 
successful, there must be multiple common loci (ie. >1% of the population) that 
influence a trait or disease risk, whereby each locus contributes a small proportion of 
overall trait variance or disease susceptibility. 
 Currently, over 800 GWAS have uncovered >5,000 associations between 
SNPs and more than 500 traits/diseases (HuGE Navigator Statistics).  Multiple study 
designs have been employed, including case-control studies, cohort studies and 
clinical trials [23, 24].  Regardless, GWAS has explained only a fraction of variance 
in the many traits investigated.  Furthermore, associations between SNPs and traits 
of interest typically exhibit small effect sizes (mean OR ~1.33) [25].  Despite what 
may appear to be a modest yield, GWAS has led to the identification of more trait-
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associated loci in the past 5 years than were identified for decades prior using 
positional cloning, candidate gene and linkage studies.  Likewise, the biological 
implications of GWAS findings still exhibit tremendous potential with regard to 
highlighting pathways involved in disease mechanism and uncovering potential 
therapeutic targets [26].  The multitude of associations between intergenic or non-
coding SNPs with different traits has also shed light upon our nascent understanding 
of gene regulation [27].  Unexpectedly, GWAS has also uncovered associations that 
are suggestive of pleiotropic effects of certain loci, suggestive of shared etiologies 
underlying previously unrelated disease processes [28]. 
 All together, GWAS is not without its benefits and limitations.  To be able to 
detect associations with very small effect sizes it is necessary to utilize enormous 
(>100,000) populations.  Multi-center cooperation and meta-analysis are currently 
leading to the realization of the required sample sizes while running the risk of 
diluting out valid associations within individual sub-populations.  The a priori 
approach of GWAS, wherein no prior assumptions are made regarding the number 
or location of variants that will be associated with a trait, likely facilitates the 
identification of novel loci.  Meanwhile, the volume of probability entailed in GWAS 
requires stringent corrections to be made for multiple testing.  Thus, many valid 
disease associations may be missed or excluded based solely upon statistical 
methods rather than experimental biology.  Hence, the biological validation of GWAS 
will present its own challenges as the number of associations being discovered 
continues to increase.  Ultimately, the premise remains that GWAS will increase the 
breadth and depth of our understanding of biological trait variance and disease 
pathogenesis. 
  
GWAS and Heritable Disease 
 
GWAS and Alzheimer’s 
 
 Alzheimer’s disease (AD) afflicts one out of eight adults over the age of 65 
living in the United States.  As of 2011, nearly half of the US population over the age 
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of 85 is affected.  AD is the fifth leading cause of death in the US and is the most 
common form of dementia.  Unlike the other ten leading causes of death in the US, 
there is no effective means to prevent or treat AD, despite being initially recognized 
more than 100 years ago.  Furthermore, the number of deaths attributable to AD has 
increased 66% between 2002-2008 while the number of deaths from heart disease, 
stroke and cancer has fallen [29].  
 There are two forms of AD that are distinguished by their age of onset, 
pattern of inheritance and to some extent their etiologies [30].  Early-onset AD 
accounts for approximately 4% of disease prevalence in the US and generally 
affects individuals under the age of 65.  Early-onset AD has a monogenetic etiology 
and is caused by mutations in genes that affect the processing of the amyloid 
precursor protein (APP, chromosome 21q21) to the neurotoxic β-amyloid peptide 
[31].  Deposition of β-amyloid plaques within the extracellular brain parenchyma was 
initially characterized by Dr. Alois Alzheimer in 1906 and is recognized as the 
neuropathological hallmark of AD [32, 33].  According to the “Aβ hypothesis”, the 
accumulation of β-amyloid is the driving force in AD pathogenesis [34].  Mutations 
within genes that affect the processing of APP to β-amyloid (eg. PSEN1 and 
PSEN2) have also been mapped to this form of AD [33].  A similar early-onset form 
of the disease also occurs in individuals with trisomy of chromosome 21 (ie. Down 
syndrome) who carry a third copy of APP, suggesting that the APP gene plays a 
central role in the pathogenesis of early-onset AD [35, 36]. 
In contrast to early-onset AD, the etiology of late-onset AD is more nebulous.  
This form of AD constitutes the majority of the disease burden (96% of disease 
prevalence in the US) and typically affects individuals over the age of 65.  Although 
the heritability of late-onset AD is high (between 60-80% by some estimates) there 
are undoubtedly both polygenic and environmental components [37-39].  The major 
genetic risk factor for late-onset AD has been mapped to the locus which codes for 
apolipoprotein E (APOE) [40-43].   
Expression of APOE, the principal genetic risk factor for late-onset AD, is 
highest in the liver and the brain, most notably in astrocytes [44, 45].  APOE is the 
predominant apolipoprotein within the CNS, along with APOJ and APOA-1 [46].  The 
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three common isoforms of APOE (APOE-ε2, -ε3 and -ε4) differ significantly in 
function and are determined by SNPs that define amino acids 112 and 158.  One 
copy of the APOEε4 allele increases the risk of AD two to three fold, whereas the 
presence of two ε4 alleles increases AD risk twelve fold [47, 48].  Presence of the 
APOEε4 allele is also associated with earlier AD age of onset [49].  It is noteworthy 
that these associations do not hold true across ethnicities, but are derived from 
studies of Caucasian populations [50, 51].   
APOE likely acts via multiple mechanisms to influence AD risk.  In the 
periphery the APOEε4 allele is associated with increased low-density lipoprotein 
(LDL) cholesterol and cardiovscular disease [52, 53].  Within the CNS, APOE likely 
mediates cholesterol transport and thus facilitates neurite outgrowth, membrane 
repair and synaptogenesis [54, 55].  To this end, APOE knockout mice display age-
dependent decreases in synaptic density and dendritic dysmorphology as early as 4 
months of age [56].  Furthermore, transgenic mice which have had the human 
APOEε4 allele knocked in exhibit impaired neurite sprouting and synaptogenesis 
following entorhinal cortex lesion [57].  Hence, APOE appears to play a crucial, 
isoform-dependent role in CNS development and maintenance. 
In addition to cholesterol transport, APOE likely plays an isoform-dependent 
role in the clearance of β-amyloid from the CNS.  This is demonstrated in part by the 
relative increase of Aβ deposition in vivo in mice which have had the human 
APOEε4 allele knocked-in as compared to mice in which human APOEε2 or ε3 was 
knocked in [58-60].  Oddly enough, a total lack of murine APOE is also associated 
with dramatically increased Aβ deposition and dystrophic neurites, suggesting that 
human APOEε4 may suffer from a lack of function with regard to Aβ clearance [60-
65].  Similarly, in vitro data suggest that complexes of APOEε4 and Aβ may be 
cleared from the CNS more slowly than Aβ in complex with APOEε2 or ε3 [66].  
Recent developments in in vivo β-amyloid imaging further support this idea based on 
evidence that APOε4 allele dosage is associated with the burden of neuritic plaques, 
even in cognitively intact subjects [67, 68]. 
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Other hypotheses exist to explain the mechanism by which APOE influences 
AD risk, including the modulation of CNS inflammation [69].  This is reflected in data 
which demonstrate that APOE-/- mice exhibit increased inflammation in response to 
β-amyloid.  Additionally, APOEε4 knock-in mice display more inflammation than ε3 
knock-in mice treated lipopolysaccharide (LPS) [70, 71].  Despite these multiple 
hypotheses, there is still no clear explanation of how APOE acts, centrally or 
peripherally, to modulate AD risk.  Furthermore, APOE genotype is neither sufficient 
nor necessary for the development of AD.  For this reason the scientific community 
has looked to GWAS for insight into other genetic risk factors and biological 
pathways that influence AD. 
Outside of the APOE locus, a multitude of genetic variants with small effect 
sizes also contribute to genetic AD risk (Table 1.1) [72].  There has been a recent 
surge in the number of such genetic variants associated with AD thanks to GWAS 
(Table 1.2).  These variants primarily consist of SNPs that implicate the loci BIN1 
(bridging integrator 1), CLU (clusterin), ABCA7 (ATP-binding cassette, subfamily A, 
member 7), CR1 (complement component receptor 1) and PICALM 
(phosphatidylinositol binding clathrin assembly protein).  Examination of the 
ontological clustering of these SNPs along with other AD genetic risk factors reveals 
that genes implicated in both cholesterol metabolism and immune system function 
are overrepresented as AD risk factors [73]. 
  
 11 
Author 
 
Year 
 
# of SNPs 
 
# AD 
Initial 
# AD 
Follow-up 
# non-AD 
Initial 
# non-AD 
Follow-up 
Hollingworth et al. 2011 496,763 6688 13182 13685 26261 
Hu et al. 2011 509,376 1831 751 1764 751 
Lee et al. 2011 627,380 549 2449 544 1390 
Naj et al. 2011 2,324,889 8309 3531 7366 3565 
Sherva et al. 2011 2,540,000 124 - 142 - 
Wijsman et al. 2011 565,336 1848 617 1991 573 
Naj et al. 2010 483,399 931 1338 1104 2003 
Seshadri et al. 2010 2,540,000 3006 6505 22604 13532 
Beecham et al. 2009 532,000 492 238 496 220 
Carrasquillo et al. 2009 313,504 844 1547 1255 1209 
Harold et al. 2009 529,205 3941 2023 7848 2340 
Heinzen et al. 2009 - 331 - 368 - 
Lambert et al. 2009 537,029 2032 3978 5328 3297 
Poduslo et al. 2009 489,218 9 199 10 225 
Potkin et al. 2009 516,645 172 - 209 - 
Abraham et al. 2008 561,494 1082 - 1239 1400 
Bertram et al. 2008 484,522 941 1767 404 838 
Li et al. 2008 469,438 753 418 736 249 
Coon et al. 2007 502,627 664 - 422 - 
Grupe et al. 2007 17,343 380 1428 396 1666 
Reiman et al. 2007 312,316 446 415 290 260 
 
Table 1.1 AD GWAS performed between 2007-2011.  Adapted from the AlzGene 
Database [74]. 
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# Gene Polymorphism Ethnicity OR (95% CI) P-value 
1 APOE APOE_e2/3/4 All 3.685 (3.30-4.12) <1x10-50 
2 BIN1 rs744373 All 1.166 (1.13-1.20) 1.59x10-26 
3 CLU rs11136000 Caucasian 0.879 (0.86-0.90) 3.37x10-23 
4 ABCA7 rs3764650 All 1.229 (1.18-1.28) 8.17x10-22 
5 CR1 rs3818361 Caucasian 1.174 (1.14-1.21) 4.72x10-21 
6 PICALM rs3851179 Caucasian 0.879 (0.86-0.9) 2.85x10-20 
7 MS4A6A rs610932 All 0.904 (0.88-0.93) 1.81x10-11 
8 CD33 rs3865444 All 0.893 (0.86-0.93) 2.04x10-10 
9 MS4A4E rs670139 All 1.079 (1.05-1.11) 9.51x10-10 
10 CD2AP rs9349407 All 1.117 (1.08-1.16) 2.75x10-09 
 
Table 1.2 List of most significantly AD-associated polymorphisms as of 2011.  
Adapted from the AlzGene Database [74](Bertram L, Nature Genetics, 2007).  Note 
that outside of APOE, most SNPs have an OR of less than 1.2, indicating that 
multiple variants with low effect sizes contribute to AD risk. 
 
The gene that currently exhibits the second strongest association with late-
onset AD, after APOE, is BIN1.  This gene was initially recognized for its potential 
role as a tumor suppressor [75].  BIN1 is ubiquitously expressed and exhibits at least 
10 unique alternatively spliced mRNA isoforms that appear to be tissue-specific  [76-
78].  The alternative splicing of BIN1 may play a role in the regulation of c-Myc 
activity and thereby affect oncogenic and cell-cycle pathways [77, 79].  BIN1 has 
also been implicated in muscle differentiation and mapped to a condition known as 
centronuclear, autosomal recessive myopathy [80-84].  Di Palo et al. 2002 provide 
evidence that BIN1 expressed in the brain plays a role in synaptic vesicle 
endocytosis and recycling using knockout mice [85].   
The function of CLU, the third most strongly AD-associated gene, is largely 
unknown.  It was initially discovered in human plasma as a mediator of the 
complement cascade and was later identified as a major secreted product of 
testicular Sertoli cells [86, 87].  Additionally, CLU is associated with HDL and thus 
represents a novel apolipoprotein that is expressed at high levels in the brain, testis, 
liver and plasma [46, 88-90].  Also known as APOJ, CLU is expressed in the human 
brain at levels that rival those of APOE, and may be involved in similar processes 
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[91-93].  Furthermore, CLU is found to be up-regulated in the AD brain and is a 
component of β-amyloid plaques [94, 95].  CLU is able to interact directly with Aβ 
peptide and, like APOE, has been implicated in the clearance of β-amyloid across 
the blood-brain barrier [96-98].  Although CLU-/- knockout mice still exhibit a 
temporal pattern of β-amyloid plaque accumulation similar to that of wild-type 
animals, they appear to accumulate less fibrillar Aβ and fewer dystrophic neurites 
[99, 100].  It is noteworthy that transgenic mice lacking both APOE and CLU exhibit 
increased soluble CSF Aβ in addition to earlier and greater β-amyloid plaque burden 
[101].  Regarding the prognostic utility of CLU, a recent study by  Schrijvers EM et al, 
JAMA, 2011 found that, while CLU is elevated in patients with AD and is correlated 
with the severity of disease, baseline measurements of CLU in non-demented 
individuals yield poor prognostic information regarding future AD incidence [102]. 
Genetic variants of ABCA7, an ATP-binding cassette (ABC) transporter, have 
been identified as AD risk factors, although none of these variants are suggestive of 
modifying gene expression or function [103, 104].  As a family, the ABC transporters 
facilitate transport of substrates across the cell membrane [105].  ABCA7 in 
particular is expressed at high levels in the brain, most notably in microglia and is 
involved in loading apolipoproteins with cell-derived lipids [106, 107].  Per 
observations made using APP overexpressing cells, there are indications that 
ABCA7 may also regulate the generation of β-amyloid [108].  
Polymorphisms within the CR1 gene came to the attention of Alzheimer’s 
researchers in 2009 thanks to GWAS published by Lambert JC, 2009 and Harold D, 
2009 [109, 110].  CR1 encodes the principal receptor for the complement C3b 
protein and is responsible for the binding and clearance of opsonized antigens [111-
114].  A number of CR1 polymorphisms have been recognized per their effects on 
red blood cell agglutination and CR1 expression [115-118].  Polymorphisms within 
CR1 have also been associated with systemic lupus erythematosus and resistance 
to malarial infection [119, 120].  Data also support an interaction between CR1 and 
Aβ that may facilitate Aβ clearance and thus modulate AD pathology [121-125].   
PICALM is involved in clathrin-mediated endocytosis and neurotransmitter 
release [126, 127].  Thus, it has been hypothesized that PICALM plays a role in APP 
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endocytosis and Aβ production [128-131]. However, recent data illustrate that RNAi 
knockdown of PICALM has no effect on the generation of β-amyloid [132].  PICALM 
is expressed ubiquitously, but displays strong expression in endothelial cells 
including human cerebral microvasculature raising the possibility that it may aid in 
the clearance of Aβ across the blood brain barrier [133].  Data also suggest that 
PICALM plays a role in neuronal outgrowth and dendritic sprouting via effects on 
intracellular trafficking [134].   
The MS4A genes are similar in gene structure and likely belong to a larger 
group of cell-surface proteins composed of four conserved transmembrane domains 
[135].  Members of this gene family may play various roles in immune system 
function, cell cycle and cancer [136-139]. 
CD33 encodes a myeloid cell surface receptor that belongs to the sialic acid-
binding immunoglobulinlike lectin family [140, 141].  CD33 also belongs to a group of 
proteins involved in cell-cell interactions that have been implicated in immune 
system regulatory functions [142].  The cytoplasmic tail of CD33 contains an 
immunoreceptor tyrosine-based inhibitory motif that triggers endocytosis of the 
receptor upon phosphorylation-dependent ubiquitylation [143].  Polymorphisms in 
the CD33 gene have been found to affect receptor mediated endocytosis upon 
antibody binding [144]. 
CD2AP is a scaffold adaptor protein that is expressed in the cytoplasm and 
interacts with the actin cytoskeleton to facilitate its rearrangement [145]. CD2AP is 
expressed within the renal glomerular apparatus where it plays a role in maintaining 
subcellular architecture [146].  Knockout of CD2AP results in congenital nephrotic 
syndrome in mice and CD2AP mutations are associated with nephrotic syndrome 
and focal segmental glomerulosclerosis in humans [147-150].  CD2AP also plays a 
likely role in receptor mediated endocytosis, T-cell receptor signaling and may exert 
anti-apoptotic effects [151, 152]. 
Thus, of the newly identified variants associated with AD, several molecular 
and biological processes can be implicated [104].  The genes PICALM, BIN1, CD33 
and CD2AP can all be linked to endocytosis.  Meanwhile, the genes APOE, CLU 
and ABCA7 can all be tied to lipid metabolism.  Last but not least, CLU, CR1, 
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ABCA7 and CD33 can also be tied to various immune system functions.  Although 
the functions of several now AD-associated loci remain unknown, their robust 
association with AD suggests that by learning their functions we will gain further 
insight into the pathogenesis of AD. 
Although far more genetic variants have been implicated in AD than those 
identified by GWAS, their robustness and validity are less certain due to the size and 
meta-analysis of GWAS.  For example, many putative genetic AD risk factors that 
were highlighted in small linkage analysis and candidate gene studies, including (eg. 
GAB2) have failed to be validated in larger, more recent studies [153, 154].  The 
failure to replicate the associations of these loci does not exclude them from 
contributing to AD pathogenesis, in part due to the limitations of GWAS that are 
discussed in the final chapter. 
Regarding the future of GWAS for discovery of AD genetic risk factors, 
several considerations have become apparent.  Among these are sample size and 
replication population size to provide sufficient power, uniform and precise AD 
diagnoses, and use of well-defined control populations [153, 154].  The utility of 
GWAS for discovering AD genetic risk factors has by no means met an end, largely 
due to recent insights into non-SNP human variation.  These variants will likely 
provide further insights into the biological processes affecting AD, but may also 
facilitate AD risk prediction [155]. 
 
GWAS and Hyperlipidemia 
 
Circulating plasma lipids, i.e. cholesterol and triglycerides, are involved in 
diverse biological processes including cell membrane construction and maintenance, 
hormone synthesis, cell signaling and energy metabolism [156].  They also carry the 
potential to adversely affect human health and are key risk factors for cardiovascular 
disease (CVD) [157-160].  It is noteworthy that CVD accounts for nearly one out of 
every three deaths in the US, and is the most prominent cause of death worldwide 
(according to WHO and CDC statistics). Furthermore, CVD is highly heritable and is 
influenced by genetic susceptibility [161].  Based on data extracted from the 
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Framingham Heart Study, more than two-thirds of men and more than half of women 
will develop some form of CVD in their lifetime [162].  Of those individuals who die 
from CVD in the US, nearly 33% of them are less than 75 years of age. 
There is a graded, continuous relationship between low-density lipoprotein 
(LDL) cholesterol and the risk of coronary heart disease.  Plasma cholesterol during 
adolescence can be used to predict nearly a 2-fold increase in risk for CVD between 
the upper and lower 25th percentiles of total cholesterol, independent of other CVD 
risk factors [163].  Roughly 50% of all US adults have a serum cholesterol 
>200mg/dL, which places them in or near the top quartile for cardiovascular risk.  
Interventions meant to lower plasma cholesterol are effective in reducing incident 
coronary artery disease (CAD), acute myocardial infarction (MI), heart disease, 
stroke and overall mortality [164-167].  Although reduction in plasma cholesterol can 
be achieved via multiple modalities, including exercise, diet and pharmaceuticals 
[168], there are profound genetic factors involved in determining plasma lipid 
concentrations as well as lipid-lowering drug response [169-171]. 
Data suggest that at least half of the variation in serum cholesterol is 
attributable to genetics [172].  This is in part reflected by the fact that ~80% of 
plasma cholesterol is synthesized endogenously [156].  Several examples of the 
impact genetics can exert on lipid homeostasis include mutations in LDLR (low-
density lipoprotein receptor), APOB (apolipoproten B), PCSK9 (proprotein 
convertase subtilsin/kinexin type 9) and ANGPTL4 (angiopoietin-like 4) that are 
capable of causing Mendelian hyper- and hypo-cholesterolemia.  Attempts to 
discover the spectrum of genetic architecture underlying lipid homeostasis via small 
linkage and association studies uncovered multiple other loci, few of which have 
ever been successfully replicated [173].  Nonetheless, data are suggestive of both 
monogenic and polygenic effects working to influence a spectrum of lipid disorders 
[174-176].   
The first reported GWAS of circulating plasma lipids, which utilized just over 
1,000 subjects from the Framingham Heart Study, was largely inconclusive [177].  
The field quickly moved to employ larger sample sizes and more densely packed 
SNP genotyping arrays, resulting in an onslaught of plasma lipid GWAS over the 
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following years [178-185].  Together, these GWAS identified robust, novel, and to 
some degree overlapping, genetic risk factors associated with variation in plasma 
lipids.  These lipid-associated SNPs conferred only a small increase or decrease in 
circulating lipid concentrations and explain only a small fraction of the variation (5-
10% cumulatively) in plasma lipids [156, 172]. 
The next step in the evolution of plasma lipid GWAS came in the form of a 
massively collaborative meta-analysis that included data from more than 100,000 
individuals of multiple ethnic backgrounds [186].  The implications of this study are 
several fold and include the demonstration of association between 95 loci (59 of 
which were previously unidentified) and plasma lipids in multiple ethnic populations.  
Furthermore, they were able to identify SNPs that were significantly associated with 
CAD, one if which (rs12916) is in tight linkage disequilibrium (r2 = 1.0) with a SNP 
that modulates splicing of HMGCR exon 13 and is associated with cholesterol-
lowering response to statins.  Among their findings were several other SNPs that 
demonstrated associations with gene expression and regulation, and when targeted 
for overexpression or knockdown were able to modulate plasma lipids in vivo in 
using mouse models.  Despite the identification of novel loci that are robustly 
associated with plasma lipids, the cumulative findings of Teslovich et al. explain a 
mere 10-12% of the overall variance in plasma lipids and approximately one quarter 
of the genetic variance [186]. 
 
SNP ID CHR LOCUS  OR/BETA  95% CI  P-VALUE 
rs2228671 19p13.2 LDLR 0.16 NR 9x10 -24 
rs693 2p24.1 APOB 0.1 NR 9x10 -23 
rs646776 1p13.3 CELSR2 0.13 NR 9x10 -22 
rs2075650 19q13.32 APOE 0.14 NR 3x10 -19 
rs3846662 5q13.3 HMGCR 0.09 NR 3x10 -19 
rs2304130 19p13.11 NCAN 0.15 NR 2x10 -15 
rs10889353 1p31.3 DOCK7 0.08 NR 4x10 -12 
rs4939883 18q21.1 LIPG 0.07 NR 2x10 -11 
rs6756629 2p21 ABCG5 0.15 NR 2x10 -11 
rs10903129 1p36.11 TMEM57 0.06 NR 5x10 -10 
 
Table 1.3 Top 10 SNP associations with Total Cholesterol.  
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SNP ID CHR LOCUS  OR/BETA  95% CI  P-VALUE 
rs1532624 16q13 CETP 0.21 NR 9x10 -94 
rs173539 16q13 CETP 0.25 0.21-0.29 4x10 -75 
rs1800775 16q13 CETP 0.18 0.16-0.20 1x10 -73 
rs3764261 16q13 CETP 3.47 NR 2x10 -57 
rs1864163 16q13 CETP 4.12 NR 7x10 -39 
rs1532085 15q22.1 LIPC 0.13 NR 1x10 -35 
rs12678919 8p21.3 LPL 0.23 0.17-0.29 2x10 -34 
rs1800588 15q22.1 LIPC 0.14 0.12-0.16 2x10 -32 
rs9989419 16q13 CETP 0.04 0.03-0.05 1x10 -32 
rs9989419 16q13 CETP 1.72 NR 3x10 -31 
 
Table 1.4 Top10 SNP associations with HDL Cholesterol. 
 
SNP ID CHR LOCUS  OR/BETA  95% CI  P-VALUE 
rs4420638 19q13.32 APOA/APOC 0.19 0.15-0.23 1x10 -60 
rs4971516 2p24.1 APOB NR 
 
2x10 -52 
rs6511720 19p13.2 LDLR 0.26 0.22-0.30 2x10 -51 
rs11591147 1p32.3 PCSK9 0.47 0.41-0.53 2x10 -44 
rs4420638 19q13.32 APOE/APOC 6.61 NR 3x10 -43 
rs12740374 1p13.3 SORT1 0.23 0.19-0.27 2x10 -42 
rs4420638 19q13.32 APOE/APOC 0.06 0.05-0.07 2x10 -40 
rs4971516 2p24.1 APOB NR 
 
2x10 -40 
rs599839 1p13.3 PSRC1 0.16 0.14-0.18 1x10 -33 
rs599839 1p13.3 SORT1 5.48 NR 6x10 -33 
 
Table 1.5 Top 10 SNP associations with LDL Cholesterol. 
 
 
Tables 1.3 – 1.6.  CHR denotes chromosomal position of SNP.  LOCUS 
includes gene(s) nearest to SNP.  OR/BETA indicate magnitude of effect size, 
together with 95% confidence interval (CI).  Data for all tables was obtained 
using the HuGE Navigator and querying for “cholesterol,” “HDL,” “LDL” or 
“triglycerides”. 
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SNP ID CHR LOCUS  OR/BETA  95% CI  P-VALUE 
rs964184 11q23.3 APOA/APOC 0.3 0.24-0.36 4x10 -62 
rs12678919 8p21.3 LPL 0.25 0.19-0.31 2x10 -41 
rs780094 2p23.3 GCKR 8.59 NR 6x10 -32 
rs1260326 2p23.3 GCKR 0.12 0.08-0.16 2x10 -31 
rs10892151 11q23.3 APOA/APOC NR 
 
3x10 -29 
rs328 8p21.3 LPL 0.19 0.15-0.23 2x10 -28 
rs12286037 11q23.3 APOA/APOC 25.82 NR 1x10 -26 
rs1558861 11q23.3 BUD13 17 13.28-20.72 2x10 -26 
rs10105606 8p21.3 LPL 0.07 0.06-0.08 4x10 -26 
rs17145738 7q11.23 MLXIPL 0.14 0.25-0.53 7x10 -22 
 
Table 1.6 Top 10 SNP associations with Triglycerides. 
 
The study design of Teslovich et al. incorporated an extraordinarily large 
sample size, multiple ethnicities, evaluation of the clinical relevance of their lipid-
associated SNPs and experimental evidence that a subset of these SNPs affect 
gene regulation.  Proposed features to be incorporated into future studies include 
evaluation of GWAS data using nonlinear models, gene-gene and gene-environment 
interactions [187].  To this end, Demirkan et al. have attempted to utilize GWAS data 
to establish additive genetic risk scores using a population of ~20,000 individuals 
[188].  Genetic risk scores were also used to predict plasma lipid concentrations in 
an independent population.  Perhaps due to their small sample size, or the lack of 
extreme phenotypes, these endeavors proved to be largely inconclusive as their 
predictive models accounted for no more than 5% variance in any lipid trait.  
Furthermore, little overlap was observed between SNPs comprising polygenic 
scores for different lipid traits, perhaps due to confounding effects of environmental 
factors on these traits.  Pathway analysis of their GWAS data also provided limited 
novel biological insight into the genetics of plasma lipids.   
Considering these data, it would appear that there are yet unidentified genetic 
variants with small effects on plasma lipids that contribute to their variance [188].  
Once again, GWAS has fallen short of explaining the heritability of a trait but at the 
same time has provide novel targets for the potential treatment of hyperlipidemia.  
And, once again, as new rare and structural variants are sequenced and maps of LD 
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are expanded and refined it may be possible to ascertain a larger proportion of 
heritability in plasma lipid traits and disorders.  The expanded capacity and 
decreasing cost of sequencing technologies may also lead to renewed interest in 
family-based linkage studies.  Regardless, a genetic framework of lipid homeostasis 
and lipid disorders is just beginning to take shape. 
 
GWAS and Rheumatoid Arthritis 
 
Rheumatoid arthritis (RA) has been recognized as a unique, debilitating 
arthritic condition since the 1800’s but lacked defined diagnostic criteria until 1987 
[189, 190].  Recently, these criteria have been updated to reflect the intent to 
diagnose RA in its earliest stages and the desire to obtain genetic signatures that 
predispose to RA risk [191].  Currently, RA affects approximately 1% of the 
developed world, especially females above the age of 65 [192-194].  RA is best 
known for its chronic, painful and irreversible joint destruction and systemic 
inflammation.  In addition to functional disabilities, RA patients often succumb to 
early mortality as a result of cardiovascular comorbidities related to persistent 
systemic inflammation [195, 196].   
It is unclear whether RA pathogenesis initiates in bone or in synovium, 
however it is clear that inflammation plays a central role in the destruction of both 
tissues [197, 198].  Autoantibodies are believed to trigger the cascade of events that 
lead to development of RA.  The majority of these antibodies are directed against 
citrullinated peptides, which are subsequently recognized by HLA receptors 
expressed by antigen presenting cells [199-202].  Signaling through HLA receptors 
triggers the production and release of key proinflammatory cytokines including TNF 
and IL-6 [203-205].  Release of these cytokines then propagates peripheral as well 
as synovial inflammation. 
Despite common themes, the RA phenotype is likely composed of multiple 
subtypes of disease that are unique in their genetic risk factors and inflammatory 
cascades [206].  Predilection for RA is highest among European and North 
American Caucasians, suggesting that genetic and/or environmental effects play a 
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role in disease development [207].  Twin studies suggest that the genetic 
contribution to RA may approximate 65% of risk [208-211].  Smoking has also 
emerged as a prominent environmental risk factor and is capable of doubling RA risk 
[212].  The interaction of smoking, genetics and RA risk is yet to be determined. 
Presently, GWAS has identified >30 SNPs that are associated with RA.  
Together these SNPs account for approximately one quarter of the genetic risk (and 
~16% of the overall risk) of RA [213, 214].  The top twelve RA-associated SNPs are 
all linked to either PTPN22 or the HLA loci.  Of the RA-associated SNPs, those 
linked to HLA genes account for ~12% of overall RA risk whereas non-HLA SNPs 
account for only ~4% of overall RA risk.  RA risk genes appear largely to fall into 
three categories based on their involvement in (i) T-cell activation (MHC genes, 
PTPN22, STAT4, CD28, CTLA4), (ii) NF-kB signaling (CD40, TRAF1, TRAF6, 
TNFSF14, TNFAIP3, c-REL), or IL2 signaling (IL2RA, IL2RB, IL2/IL21) [215].  
Interestingly, as the number of loci associated with RA is expanding, there is 
increasing evidence that genetic overlap exists between RA and other autoimmune 
diseases including type 1 DM, MS, psoriasis, SLE, Crohn’s and celiac disease [214, 
216-218]. 
 
SNP CHR LOCUS  OR/BETA 95% CI P-VALUE 
rs6910071 6p21.32 HLA-DRB1 2.88 2.73-3.03 1x10 -299 
rs6457620 6p21.32 HLA-DRB1 2.55 2.40-2.71 4x10 -186 
rs660895 6p21.32 HLA-DRB1 3.62 NR 1x10 -108 
rs6457617 6p21.32 HLA-E 2.36 1.97-2.84 5x10 -75 
rs2476601 1p13.2 PTPN22 1.94 1.81-2.08 9x10 -74 
rs13192471 6p21.32 HLA-DRB1 1.97 1.82-2.14 2x10 -58 
rs6679677 1p13.2 PTPN22 1.79 1.65-1.94 6x10 -42 
rs9296015 NR HLA locus NR 
 
2x10 -38 
rs615672 6p21.32 HLA-DRB1 NR 
 
8x10 -27 
rs7765379 6p21.32 HLA-DRB1 2.51 NR 5x10 -23 
 
Table 1.7 Top 10 RA-Associated SNPs.  These data were adapted from the 
HuGE Navigator database for the trait “Rheumatoid Arthritis”; NR – not 
reported. 
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Currently, there is no means to predict exactly which individuals with early 
signs of inflammatory arthritis will go on to develop RA or who will respond to drug 
therapy [219].  The development of biological agents directed toward reducing 
inflammation, T-cell activation and cytokine production carries some promise for 
disease treatment but also the threat of adverse side effects and increased mortality 
[220].  Thus, the primary treatment of RA consists of analgesics, anti-inflammatory 
medications and disease-modifying antirheumatic drugs (DMARDS, eg. 
Methotrexate), although the mechanisms of the latter are not completely understood.  
Perhaps insights from GWAS will contribute to our understanding of disease and 
DMARD mechanisms, allowing for more efficacious therapies in the future. 
 
GWAS and Diabetes Mellitus 
 
Diabetes mellitus (DM) is a collection of disorders, all of which result in 
pathologically elevated levels of blood glucose.  It was the Indian physician Sushruta 
who first described the symptomatic appearance of excess glucose in the urine, 
resultant of DM, in 400 B.C.  Fast-forward several thousand years and DM now 
affects nearly 10% of the US population and is the seventh leading cause of death.  
Mortality aside, DM is also a major risk factor for CVD, renal failure and blindness 
[221]. 
The most common forms of diabetes are referred to as Type 1 DM (T1DM, 5-
10% of disease burden) and Type 2 DM (T2DM, 90-95% of disease burden).  Other, 
infrequent categories of DM include gestational diabetes (often the result of maternal 
T2DM) and multiple, rare monogenic forms of DM [222].  Although elevated blood 
glucose is pathognomonic for DM, the etiologies underlying T1DM and T2DM are 
quite different.  Patients with T1DM often suffer an insidious onset of the disease in 
childhood or adolescence resulting from autoimmune-mediated destruction of 
pancreatic, insulin-secreting β-cells.  Patients with T2DM are characteristically 
overweight adults, and increasingly overweight adolescents, who also suffer an 
insidious onset of disease marked by initial declines in peripheral insulin sensitivity 
and eventually deficient insulin secretion and peripheral insulin resistance. 
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Both T1DM and T2DM display an increased incidence within families.  
Furthermore, studies of monozygotic twins with DM suggest that the genetic 
component of both T1DM and T2DM risk is between 25-65% [223-228].  The pattern 
of T1DM inheritance is complex and up to 90% of new-onset patients have no family 
history of T1DM, suggesting a polygenic etiology that may require interactions with 
environmental triggers [229, 230].  Up to 50% of the genetic risk for T1DM can be 
explained by the ~4,000 kilobase HLA region, which contains over 200 genes and 
confers an OR of ~6.75 for development of T1DM [231-234].  More specifically, 
children who carry the high-risk class II HLA-DR3/4, -DQ8 alleles account for nearly 
50% of individuals who exhibit autoimmune β-cell destruction by 5 years of age [228].  
The mechanistic contributions of HLA loci in T1DM is unclear, however data suggest 
that the process is immune-mediated, whereby certain HLA alleles predispose to 
auto-antigen recognition, antigen presentation, T-cell activation and autoimmune 
destruction of insulin-secreting β-cells [235-237].  It has also been documented that 
several HLA alleles influence T1DM age-of-onset, suggesting that there may be 
additive effects stemming from these loci [238, 239]. 
 
SNP CHR LOCUS OR/BETA 95% CI P-VALUE 
rs9272346 6p21.32 HLA-E 5.49 4.83-6.24 5x10 -134 
rs9272346 6p21.32 HLA NR 
 
6x10 -129 
rs9268645 6p21.32 HLA-E NR 
 
1x10 -100 
rs2476601 1p13.2 PTPN22 NR 
 
9x10 -85 
rs2476601 1p13.2 PTPN22 1.98 1.82-2.15 2x10 -80 
rs7111341 11p15.5 INS NR 
 
4x10 -48 
rs6679677 1p13.2 PTPN22 NR 
 
1x10 -40 
rs10509540 10q23.31 RNLS 1.33 1.25-1.43 1x10 -28 
rs3184504 12q24.12 SH2B3 NR 
 
3x10 -27 
rs6679677 1p13.2 PTPN22 1.82 1.59-2.09 5x10 -26 
 
Table 1.8 Top 10 T1DM-Associated SNPs. These data were adapted from the 
HuGE Navigator database for the trait “Type 1 Diabetes Mellitus”; NR – not 
reported. 
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Beyond the HLA region, associations with more than 50 other loci have been 
identified and summarized by the Type 1 Diabetes Genetics Consortium [240].  
Several of these loci were initially identified by linkage analysis or via the candidate 
gene approach and include INS (insulin), CTLA4 (cytotoxic T-lymphocyte-associated 
protein 4), PTPN22 (protein-tyrosine phosphatase, non-receptor type 22) and IL2RA 
(interleukin 2 receptor alpha) [236].  Together, these initially identified loci implicate 
insulin secretion and the immune system in the pathophysiology of T1DM.  These 
loci have also been replicated for their association with T1DM in recent GWAS, and 
meta-analysis has revealed more than 40 loci associated with T1DM that exhibit 
robust associations (p < 10-6) and effect sizes ranging from OR 1.05 – 2.38 [241, 
242].  Collectively these loci further suggest a role for the immune system in the 
etiology of T1DM.  A number of these genes are also highly expressed in β-cells, 
although many lack a known function [243].  Currently, genetic risk scores based on 
GWAS data and family history are being used to identify patients for primary 
prevention trials using autoantigen vaccination and pre-symptomatic insulin 
administration [244]. 
The large genetic component attributable to T2DM risk may be due to the 
“thrifty gene” hypothesis of James Neel [245].  This hypothesis suggests that genetic 
variants associated with increased survival during times of famine (eg. via increased 
fat storage) now promote the pathogenic obesity that is central to T2DM.  The 
validity of this hypothesis is reflected in the US obesity epidemic and concurrent 
doubling of T2DM incidence over the past 20 years [246].  Since the incidence of 
T2DM in at-risk individuals (overweight, impaired glucose tolerance) can be halved 
by implementing dietary and lifestyle changes aimed at weight reduction the value of 
T2DM genetics may be underappreciated [247].  It is, however, clear that even with 
lifestyle changes, T2DM is not entirely preventable given current clinical and 
pharmaceutical resources.  Thus, the impetus for T2DM genetic research is the 
hope that at-risk individuals can be identified during childhood and that new targets 
will be discovered for treatment of symptomatic individuals. 
GWAS of T2DM have made evident the overall minor contributions of 
common genetic variants to disease risk [248].  However, several promising genetic 
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variants have come from the combination of linkage, candidate gene and association 
studies.  Both PPARG (peroxisome proliferator-activated receptor gamma – a target 
of thiazolidinediones) and KCNJ11 (potassium inwardly rectifying channel, subfamily 
J, member 11 – a target of sylphonylureas) harbor risky alleles that increase the risk 
of T2DM by 15-20% [249, 250].  Rare mutations in both of these genes are also 
know to cause monogenic diabetic syndromes characterized by impaired β-cell 
function and insulin resistance [251, 252].  The gene FTO (fat mass and obesity 
associated) which is associated primarily with BMI is also associated with T2DM, 
further emphasizing the role of obesity in T2DM risk [253].  In the advent of the 
GWAS era, the gene most strongly associated with T2DM is TCFL72 (transcription 
factor 7-like 2), which plays a role in Wnt-signaling and perhaps β-cell function as 
well [248, 254, 255].  GWAS in non-European populations have replicated many of 
the results observed in Europeans, in addition to identifying new T2DM-associated 
loci such as KCNQ1 (potassium voltage-gated channel, KQT-like subfamily, member 
1), thus strengthening the probability that these T2DM-associate genetic variants 
confer disease risk [256-259].  Cumulatively, T2DM-associated loci appear to play a 
role in β-cell function, insulin secretion, insulin resistance and obesity [260]. 
  
SNP CHR LOCUS  OR/BETA  95% CI P-VALUE 
rs7903146 10q25.2 TCF7L2 1.4 1.34-1.46 2x10 -51 
rs7901695 10q25.2 TCF7L2 1.37 1.31-1.43 1x10 -48 
rs2237892 11p15.5 KCNQ1 1.4 1.34-1.47 2x10 -42 
rs2383208 9p21.3 CDKN2 1.34 1.27-1.41 2x10 -29 
rs1552224 11q13.4 ARAP1 1.14 1.11-1.17 1x10 -22 
rs10440833 6p22.3 CDKAL1 1.25 1.20-1.31 2x10 -22 
rs7578326 2q36.3 IRS1 1.11 1.08-1.13 5x10 -20 
rs4712523 6p22.3 CDKAL1 1.27 1.21-1.33 7x10 -20 
rs8050136 16q12.2 FTO 1.3 1.23-1.39 2x10 -17 
rs2237897 11p15.4 KCNQ1 1.33 1.24-1.41 1x10 -16 
 
Table 1.9 Top 10 T2DM-Associated SNPs. These data were adapted from the 
HuGE Navigator database for the trait “Type 2 Diabetes Mellitus”; NR – not 
reported. 
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Although T2DM-associated variants can aid in the discrimination of the 
genetically extreme at-risk and protected individuals, they have little cumulative 
ability to improve clinical risk prediction in the general population compared to 
traditional measures of age, BMI and gender [261].  GWAS of fasting glucose traits 
suggest that the genetics underlying β-cell function and insulin resistance do not 
overlap significantly and that loci that control physiologic glucose metabolism may 
not reflect the pathologic nature of T2DM glucose intolerance [262].  Thus, 
identification of precise causal variants and further insight into the biological 
relevance of these variants will be required. Presently identified genetic risk factors 
for T2DM explain only 10% of the expected genetic contribution to disease risk [263].  
Invariably, the identification of low-frequency variants with increased penetrance will 
further our understanding of T2DM genetic risk. 
 
Summary 
 
The past decade has brought a bounty of genetic variants to light with regard 
to their contribution to human disease and disease-related traits.  Despite 
tremendous advances in identifying the genetic architecture of complex human 
diseases and phenotypic variance, it remains to be seen what role many of these 
variants or nearby loci play in the disease process.  By their nature, association 
studies are unable to prove causality.  Thus, a tremendous amount of work remains 
to determine the biological significance of these recently discovered associations. 
In my research I have focused on the intersection of genetic variants 
associated with AD and several related conditions.  I have furthermore attempted to 
determine the functional properties of several variants within these intersections.  
The following chapters detail a novel approach toward assessing genetic overlap 
between AD and epidemiologically-related conditions.  Also presented are my 
findings that cholesterol-associated SNPs contribute significantly to AD risk, unlike 
SNPs associated with rheumatoid arthritis or diabetes mellitus.  Functional data is 
provided regarding several variants associated with both AD and cholesterol or AD 
and rheumatoid arthritis.  The mechanistic implications of my findings are discussed 
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along with considerations for future studies of human genetic variation with regard to 
disease risk and mechanisms of disease.   
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CHAPTER TWO 
 
EVALUATION OF THE GLOBAL ASSOCIATION BETWEEN CHOLESTEROL-
ASSOCIATED POLYMORPHISMS AND ALZHEIMER’S DISEASE SUGGESTS A 
ROLE FOR RS3846662 AND HMGCR SPLICING IN DISEASE RISK 
 
 
Background 
 
Late-onset Alzheimer’s disease (AD) is a devastating form of dementia with 
no clear etiology.  As much as 80% of age-adjusted AD risk may be genetic based 
upon studies of monozygotic twins [38, 39].  The primary genetic modulators of AD 
risk are the alleles of the gene encoding apolipoprotein E (APOE), i.e. APOE-ε2, 
APOE-ε3 and APOE-ε4.  The presence of APOE-ε4 alone accounts for up to 53 % 
of AD risk while the presence of APOE-ε2 is protective against the disease [264-266].  
Multiple theories have been proposed to account for the mechanism 
underlying the association of APOE with AD [267, 268].  One theory suggests that 
the alleles of APOE modulate AD risk via their effects on cholesterol homeostasis.  
This is supported by evidence that the APOE-ε4 and APOE-ε2 alleles are associated 
with increased and decreased levels of plasma cholesterol, respectively [53].  
Furthermore, elevated midlife cholesterol is itself a risk factor for AD, raising the 
possibility that genetic modulators of cholesterol may also modulate AD risk [269, 
270].  To this end, prior studies have demonstrated variable associations between 
polymorphisms in genes related to cholesterol metabolism and AD risk [271-273].   
However, ontological analysis indicates that genes involved in cholesterol 
metabolism are significantly overrepresented as being associated with AD [73].  
Genome-wide association studies (GWAS)s have recently uncovered single 
nucleotide polymorphisms (SNP)s that are robustly and reproducibly associated with 
total cholesterol, low-density lipoprotein (LDL) and/or high-density lipoprotein (HDL) 
[178-184, 274, 275].  As such, these SNPs are essentially unequivocally associated 
with cholesterol and hence serve as outstanding tools to evaluate the genetic 
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relatedness between cholesterol and AD.  Thus, based on (i) the significant 
heritability of AD, (ii) the robust involvement of APOE in AD risk, (iii) a growing body 
of evidence that cholesterol itself modulates AD risk and (iv) the ontological 
overrepresentation of cholesterol gene variants in AD GWAS results we hypothesize 
that SNPs associated with peripheral cholesterol via GWAS also contribute to AD 
risk. 
To test this hypothesis, we evaluated SNPs associated with plasma total 
cholesterol, LDL and HDL for their association with AD risk.  Our results indicate that, 
as a group, these SNPs are significantly associated with AD.  Additionally, 
rs3846662 and rs1532085 are also associated with AD age-of-onset.  In vivo, 
rs3846662 is associated with HMGCR exon 13 inclusion in human liver but lacks a 
clear association with HMGCR splicing in human brain.  HMGCR staining in brain 
indicated that the enzyme is expressed in both neurons and glia.  Thus, we 
evaluated the function of rs3846662 in vitro using human liver- and CNS-derived cell 
lines, where rs3846662 was associated with the splicing efficiency of HMGCR exon 
13 in both cell types.  In conclusion, cholesterol-associated SNPs identified by 
GWAS, as a group, are associated with AD and exhibit the potential to elucidate 
novel mechanisms underlying AD risk and age-of onset. 
 
Results 
 
Cholesterol-associated SNPs are also associated with AD 
 
A review of GWAS via the HuGE Navigator database identified eighteen non-
redundant SNPs whose associations with total cholesterol, LDL and/or HDL are 
highly significant (p < 1x10-10) and have been replicated in at least two populations.  
To assess the contribution of these SNPs to AD risk we queried their association 
with AD using a three-phase approach. 
Phase 1 association testing between these eighteen cholesterol-associated 
SNPs and AD was performed by using 843 AD and 1,264 non-AD samples.  PLINK 
was used to test for SNP-AD associations per additive models for the eighteen 
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cholesterol-associated SNPs.  Of the eighteen SNPs, rs157580 is in linkage with 
APOE and served as a positive control for AD association.  In our Phase I study 
population, rs157580 and was significantly associated with AD in an additive model 
(p = 3.0x10-22, OR = 0.51).  Henceforth only seventeen cholesterol-associated SNPs 
were considered for the purpose of multiple testing. 
Global analysis of all seventeen cholesterol-associated SNPs revealed that, 
as a group, these SNPs are significantly associated with AD (p = 0.017, Table 1A).  
Furthermore, two of these SNPs exhibited nominally significant associations with AD 
(p < 0.05, Table 1B).  These SNPs are located in or near the genes HMGCR 
(rs3846662) and MMAB/MVK (rs2338104).  Three additional SNPs exhibited trends 
with AD (p < 0.1), including rs1363232 (TIMD4/HAVCR1), rs1532085 (LIPC) and 
rs9989419 (CETP). 
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CHR GENE SNP OR L95 U95 P 
19 APOE rs157580 0.51 0.45 0.59 3.30E-21 
5 HMGCR rs3846662 1.16 1.02 1.32 0.02 
12 MMAB/MVK rs7298565 0.88 0.78 1.00 0.05 
5 TIMD4/HAVCR1 rs1363232 0.89 0.78 1.01 0.06 
15 LIPC rs1532085 0.89 0.78 1.01 0.07 
16 CETP rs9989419 1.12 0.98 1.27 0.09 
19 NCAN rs2304130 1.16 0.92 1.47 0.21 
20 HNF4A rs1800961 0.80 0.55 1.16 0.24 
18 LIPG rs4939883 1.09 0.92 1.28 0.32 
16 LCAT rs2271293 0.91 0.75 1.10 0.33 
1 SORT1 rs646776 1.07 0.92 1.24 0.40 
1 GALNT2 rs10779835 0.95 0.84 1.08 0.44 
9 TTC39B rs471364 1.07 0.88 1.30 0.48 
2 APOB rs506585 1.05 0.90 1.23 0.53 
19 LDLR rs2228671 0.96 0.79 1.17 0.66 
2 APOB rs693 0.98 0.87 1.11 0.78 
16 CETP rs3764261 0.99 0.86 1.13 0.86 
9 ABCA1 rs3847303 0.99 0.82 1.19 0.92 
 
Table 2.1  Phase 1 analysis of association between cholesterol SNPs and AD.  
(A) Overall, the seventeen SNPs not in linkage with APOE exhibited a global 
association with AD by using multivariable logistic regression (p = 0.017).  (B) Two 
SNPs, not including rs157580 (which marks APOE), were nominally associated with 
AD per additive logistic regression modeling (p < 0.05).  Three other SNPs showed a 
trend with AD (p < 0.1).   
 
Three of the SNPs that demonstrated a nominal association or trend with AD 
(p < 0.1) have also been associated with gene regulation.  Rs3846662 has been 
associated with statin responsiveness via an intermediate effect on HMGCR exon 13 
alternative splicing [276, 277].  Rs2338104 is associated with MMAB mRNA and 
protein levels in human liver [278].  Rs1532085 has been implicated in LIPC 
expression in human liver [186]. 
To focus upon SNPs with the potential to provide mechanistic insights into AD 
risk, we pursued these three SNPs which (i) demonstrated nominally significant 
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association or a trend with AD in Phase 1 and (ii) have been implicated in gene 
regulation.  Thus, in Phase 2 of our study, we evaluated rs3846662, rs2338104 and 
rs1532085 in 1,097 AD and 2,661 non-AD samples for their association with AD.  
Although Phase 2 associations with AD did not reach significance, these results 
showed a similar trend in odds ratios for rs3846662 and rs1532085; rs7298565 
demonstrated an inconsistent odds ratio for AD risk (Table 2).   
 
CHR GENE SNP OR L95 U95 P 
5 HMGCR rs3846662 1.08 0.98 1.20 0.13 
12 MMAB/MVK rs7298565 1.08 0.98 1.19 0.13 
15 LIPC rs1532085 0.95 0.86 1.05 0.30 
 
Table 2.2  Phase 2 analysis of association between cholesterol SNPs and AD.  
The three SNPs from Phase 1 that were either nominally associated or trended with 
AD and are associated with gene regulation were tested for their association with AD 
in a second case-control population.  While both rs3846662 and rs7298565 trended 
with AD, only rs3846662 exhibited a consistent odds ratio, i.e. the minor allele 
trended with increased AD risk. 
 
Since our phase 1 and phase 2 populations were drawn from the same larger 
series, and to obtain maximum statistical power, we also analyzed a combined 
Phase 1 and Phase 2 population.  Analysis of these 1,940 AD and 3,925 non-AD 
samples suggested that both rs3846662 and rs1532085 are associated with AD (p = 
0.004 and p = 0.03, respectively, Table 3).  Moreover, since the alleles of APOE 
demonstrate an effect on age of AD onset, we sought to gain further insights into the 
actions of rs3846662 and rs1532085 by testing for their effects on age-of-onset [266].  
After stratifying for copies of the APOE-ε4 allele, carriers of the rs3846662_G allele 
have a significantly earlier onset of AD compared to non-carriers (p = 0.003, OR = 
1.141, Figure 1A-C).  Likewise, individuals homozygous for the rs1532085_A allele 
had a significantly later onset of AD than carriers of the G allele (p = 0.005, OR = 
0.788, Figure 1D-F).  Thus, both rs3846662 and rs1532085 are significantly 
associated AD age-of-onset. 
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CHR GENE SNP OR L95 U95 P 
5 HMGCR rs3846662 1.12 1.04 1.21 0.004 
15 LIPC rs1532085 0.92 0.85 0.99 0.03 
12 MMAB/MVK rs7298565 0.99 0.92 1.07 0.88 
 
Table 2.3  Phase 3 analysis of association between cholesterol SNPs and AD.  
Phase 1 and Phase 2 populations were combined to allow for testing of SNP-AD 
associations under maximal power (80% for rs3846662 and 98% for rs1532085).  
Both rs3846662 and rs1532085 exhibited significant associations with AD in this 
combined population per logistic regression (p < 0.05). 
 
 
Figure 2.1  Both rs3846662 and rs1532085 are significantly associated with AD 
age-of-onset.  (A-C) Carriers of the rs3846662_G allele exhibit a significantly earlier 
onset of AD than AA homozygotes, stratified by the number of APOE-ε4 alleles 
present.  (D-F) Individuals homozygous for the A allele of rs1532085 exhibit a 
significantly later onset of AD than carriers of the G allele, again stratified by the 
number of APOE-ε4 alleles present.  (A/D – no APOE-ε4, B/E – 1 copy of APOE-ε4, 
C/F – 2 copies of APOE-ε4). 
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Rs3846662 and HMGCR splicing and expression in vivo 
 
Since rs3846662 has been associated in vitro with HMGCR exon 13 splicing 
and with statin responsiveness, and since the contribution of statin pharmacotherapy 
to AD risk reduction is controversial, we chose to focus upon the actions of this SNP 
in further studies [276, 277, 279-281].  We began by testing for an association 
between rs3846662 and HMGCR exon 13 splicing in vivo using cDNA from human 
liver and brain, both of which are major cholesterol biosynthetic organs.  HMGCR 
splicing was quantified as the percentage of HMGCR∆13 (calculated as HMGCR∆13 
/ (HMGCR∆13 + HMGCR_FL)). 
In liver, we found that rs3846662 was significantly associated with HMGCR 
exon 13 splicing (p = 0.026 per ANOVA, Figure 2).  Overall, HMGCR∆13 
represented 35.8 ± 12.2% of total HMGCR mRNA, with average percent 
HMGCR∆13 values for rs3846662 AA and GG individuals differing by 16.5%.   In 
contrast, human brain was significantly more efficient at retaining exon 13  (p < 
0.001, Student’s t-test), with the average percentage of HMGCR∆13 being 21.8 ± 
11.1%.  Moreover, a trend was not detected between rs3846662 and HMGCRΔ13 
percentage in the brain (Figure 3).  In considering this result, we noted that HMGCR 
exon 13 splicing exhibits substantial variation among tissues [282].  Since brain is a 
particularly cell-type heterogeneous tissue, we hypothesized that our ability to detect 
an association between rs3846662 and HMGCR exon 13 splicing in human brain is 
confounded by HMGCR expression in multiple cell types within the brain.   
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Figure 2.2  Rs3846662 is significantly associated with percent HMGCR∆13 in 
human liver.  Individuals homozygous for the G allele of rs3846662 exhibit the most 
efficient splicing of HMGCR exon 13 (p = 0.026, ANOVA.  We note that GG 
homozygotes also exhibit an increased risk of AD and exhibit increased total and 
LDL cholesterol. 
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Figure 2.3  Rs3846662 is not associated with percent HMGCR∆13 in human 
brain.  However, we are underpowered to observe a significant difference (p < 0.05) 
in percent HMGCR∆13 between rs3846662 genotypes given the overall high level of 
exon 13 inclusion in brain cDNA and the possibility that rs3846662 may affect 
HMGCR exon 13 in a cell-type dependent manner. 
 
 To investigate this hypothesis, we performed HMGCR immunostaining in 
human anterior cingulate.  Both neurons and astrocytes expressed HMGCR as 
indicated by its co-localization with neuron-specific MAP2 (Figure 4A) and glia-
specific GFAP (Figure 4B).  Thus, possible differences in basal exon 13 splicing 
between neurons and astrocytes may obscure our ability to detect an association 
between rs3846662 and HMGCR exon 13 splicing in human brain. 
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Figure 2.4  Immunostaining reveals that HMGCR is present in both neurons 
and glia.  (A-C) HMGCR (A) is expressed within MAP2 labeled neurons (B) per 
merging of the two images (C).  (D-F)  Likewise, HMGCR (D) is also expressed in 
GFAP positive glia (E) per merging of the two images (F).  Size bars in A and D 
represent 50µm. 
 
Effect of rs3846662 on splicing in-vitro using liver and brain cell lines 
 
To compare HMGCR exon 13 splicing in homogeneous cell types reflective of 
liver and brain, we tested the effects of rs3846662 on HMGCR minigene splicing in 
hepatocellular carcinoma HepG2 and neuroglioma H4 cell lines.  In both cell lines, 
the rs3846662_G allele was associated with increased retention of HMGCR exon 13 
relative to the rs3846662_A allele.  In HepG2 cells, the rs3846662_G allele was 
associated with 12.9 ± 5.7% more HMGCR exon 13 retention (p = 0.02, Figure 5A).  
Similarly, in H4 cells, the rs3846662_G allele was associated with 5.1 ± 2.3% more 
HMGCR exon 13 retention (p=0.02, Figure 5B).  In summation, rs3846662 is 
 38 
associated with HMGCR exon 13 splicing in human liver and in cell lines derived 
from liver and brain.    
 
 
Figure 2.5  Rs3846662 functionally modulates percent HMGCR∆13 in vitro in 
HepG2 and H4 cells.  Transfection of HepG2 (A) and H4 (B) cells with mini-gene 
splicing vectors containing HMGCR exons 12-14 and either the A or G allele of 
rs3846662 revealed a significant difference in HMGCR exon 13 splicing efficiency 
between alleles (p = 0.02 for each, paired student’s t-test). 
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Discussion 
 
 The primary findings of our study are that: (1) SNPs unequivocally associated 
with plasma cholesterol demonstrate a significant global association with AD risk, (2) 
rs3846662 and rs1532085 are associated with AD age-of-onset, (3) rs3846662 is 
associated with HMGCR exon 13 splicing in human liver in vivo and in brain and 
liver-derived cell lines in vitro. 
 Our understanding of CNS cholesterol homeostasis is in its infancy relative to 
peripheral cholesterol homeostasis [283-286].  CNS cholesterol, under normal 
physiologic conditions, is maintained as a separate pool from plasma cholesterol by 
the blood brain barrier [287].  The SNPs studied here were chosen because they 
were unequivocally associated with plasma cholesterol per se [73, 272, 273, 288].  
Hence, these SNPs, which also are also globally associated with AD risk, may 
influence AD via (1) peripheral effects on vasculature, and/or (2) direct effects on 
CNS cholesterol homeostasis.   
Two lines of evidence support the possibility that these SNPs influence AD 
risk via vascular effects.  First, the genes associated with the majority of the tested 
SNPs are expressed at low levels in the brain compared to peripheral tissues, e.g., 
MMAB/MVK, TIMD4/HAVCR1, LIPC and CETP [289].  Hence, SNPs in these genes 
are unlikely to influence CNS cholesterol.  Second, these SNPs are capable of 
impacting human disease in the periphery, as they have been associated with 
coronary artery disease [178, 184, 290].  For example, rs3846662 was associated 
with myocardial infarction risk in an Asian population [291].  However, SNPs which 
have the largest effects on plasma cholesterol did not exhibit the most significant 
associations with AD, as perhaps would be expected if plasma cholesterol is indeed 
the primary risk factor for AD [178-184, 274, 275].  
 The primary evidence supporting a role for at least a subset of the SNPs to 
act centrally is that APOE and HMGCR are both expressed at relatively high levels 
in the brain [289]. Regarding HMGCR, rs3846662 is associated with HMGCR exon 
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13 splicing in vivo in human liver and in vitro in brain and liver-derived cell lines, as 
well as lymphocytes [277].  Rs3846662 is not significantly associated with HMGCR 
exon 13 splicing in brain, however the association exhibits a similar trend as in liver.  
Thus, we speculate that rs3846662 may still be functional in brain but its effects on 
HMGCR exon 13 splicing are confounded by cell-type heterogeneity in the CNS 
since (i) the basal exon 13 splicing efficiency varies between cell types and (ii) 
human brain cDNA samples contain differing proportions of neurons and astrocytes, 
both of which express HMGCR [277, 282].  Thus rs3846662_G may function in brain 
to increase HMGCR exon 13 retention, as observed in liver, although this effect is 
not discernible on the background of variation in HMGCR splicing in multiple brain 
cell types.  Hence, SNPs related to APOE and HMGCR may act within the CNS.  
However, central and peripheral SNP effects are not necessarily mutually exclusive 
[292-294].  A future GWAS of CNS cholesterol would further clarify the role of SNPs 
in brain cholesterol metabolism and AD risk.  
Lastly, our finding regarding rs3846662 may contribute to understanding of 
the therapeutic potential of statins in AD.  The rs3846662_A allele is associated with 
decreased HMGCR activity as reflected by decreased LDL-cholesterol (Figure 6) 
[178-180, 277].  Statins also inhibit HMG-CoA reductase and robustly reduce LDL-
cholesterol.  Additionally, statins have been associated with reduced AD risk in 
multiple retrospective studies [295-297].  However, recent studies evaluating statins 
and AD have provided mixed results [280, 281, 298-301].  While the lack of 
consistent results could be accounted for by factors such as trial duration and 
variation in statin blood-brain barrier permeability, the genetics of HMGCR are also 
known to modulate statin-responsiveness, i.e., rs3846662_A is associated with a 
blunted response to statin therapy (Figure 6) [276, 302, 303].  This phenomenon has 
been attributed to an increased proportion of HMGCR lacking exon 13, which 
encodes a portion of both the active site of the enzyme and the statin binding site 
[304-306].  Hence, rs3846662_A homozygous individuals may be less likely to 
respond to statins in AD trials.  Conversely, rs3846662_G carriers are more likely to 
respond to statin therapy in AD trials.  Furthermore, rs3846662_G carriers appear to 
be at greater risk for AD, and thus have greater benefit from statin therapy.  Hence, 
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prevention trials of statin therapy for AD may benefit from consideration of 
rs3846662 genotype to better predict responders from non-responders. 
 
 
Figure 2.6  The alleles of rs3846662 differentially affect HMGCR exon 13 
splicing, statin responsiveness, LDL cholesterol and potentially AD risk.  
Individuals carrying the rs3846662_G allele are prone to retain HMGCR exon 13, 
resulting in a greater proportion full-length HMGCR mRNA (% HMGCR_FL) and 
thus higher LDL cholesterol as a result of increased cellular HMGCR activity.  
Consequently, AD risk may be increased in these individuals due to a peripheral 
effect on plasma LDL and/or a central effect on HMGCR.  Individuals carrying 
rs3846662_G, who are prone to both increased LDL and AD risk, are also predicted 
to be more responsive to stain therapy than individuals homozygous for the 
rs3846662_A allele (who tend to inefficiently splice HMGCR exon 13).  Thus, 
rs3846662 genotype may not only increase AD risk but may also help separate 
potential responders from non-responders in statin trials to prevent AD. 
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Conclusions 
 
 In conclusion, we report that SNPs which are robustly associated with 
peripheral cholesterol are globally associated with AD risk.  Two SNPs in particular, 
rs3846662 and rs1532085, are associated with the age of AD onset.  We also 
propose a model wherein rs3846662 acts to modulate HMGCR exon 13 splicing, 
plasma cholesterol and AD risk.  Essentially, carriers of the rs3846662_G allele 
retain exon 13 of HMGCR more efficiently than rs3846662_A carriers.  This relative 
increase in production of full-length HMGCR leads to increased basal cholesterol 
and, over the lifespan of an individual, increased AD risk.  Lastly, rs3846662_G 
individuals appear to be at greater risk for AD and to be more likely to benefit from 
statin therapy to reduce AD risk. 
 
Methods 
 
SNP Selection  
 
We performed a review of GWAS literature pertinent to human plasma 
cholesterol phenotypes by querying the Human Genome (HuGE) Navigator 
(www.hugenavigator.net) with the search term “cholesterol” and then focusing upon 
the traits of total cholesterol, LDL and HDL [307].  We identified 77 unique SNPs, 
located in or near 56 genes, associated with plasma total cholesterol, LDL and HDL.  
For each of these SNPs, a significant association with plasma cholesterol was 
observed in an initial study population and at least one confirmatory population.  To 
limit multiple testing issues, we set a cutoff for significance of p<1x10-10, which 
yielded 50 SNPs.  These data were further filtered based on linkage disequilibrium.  
SNPs found to be in strong LD (r2 > 0.8 according to the CEU HapMap population) 
were considered to be redundant and only the most significantly cholesterol-
associated SNP was retained for further analysis [16].  As a result, our final dataset 
represented 18 unique SNPs residing in or near a total of 34 different genes.  One of 
these SNPs, rs157580, is located in the gene TOMM40 and resides within a 
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haplotypic block that includes the APOE gene.  Rs157580 has been previously 
associated with AD and thus was considered a positive control for AD association in 
the present study [308, 309]. 
 
Populations and Genotyping 
 
Testing for an association between the eighteen cholesterol-associated SNPs 
and AD was performed by using a case-control population consisting of 1,940 AD 
and 3,925 non-AD subjects that has been previously described [310, 311].  Briefly, 
we utilized subjects recruited for the Mayo Clinic case-control series that consisted 
of Caucasian individuals residing within the United States.  Subjects were pooled 
from three separate series, including two having received clinical diagnoses of 
probable AD according to NINCDS-ADRDA criteria from Jacksonville, FL (JS) and 
Rochester, MN (RS) and age-matched controls with a score of 0 on the Clinical 
Dementia Rating scale.  The third population was taken from the Mayo Clinic 
Jacksonville, FL brain bank (AUT) and had received autopsy-confirmed diagnoses of 
AD (NINCDS-ADRDA, Braak score >4.0) or were chosen as controls (Braak <2.5, 
not including other unrelated pathology).  
DNA from these individuals was used to evaluate an association between 
cholesterol-associated SNPs and AD in three phases.  Phase 1 was designed to 
identify cholesterol-associated SNPs that are nominally associated with AD.  Phase 
2 was designed to follow up nominally significant Phase 1 SNPs, focusing upon 
SNPs that had also been associated with gene regulation.  Phase 3 tested for SNP 
association with AD in a combined population of both Phase 1 and Phase 2 subjects 
to maximize statistical power.  
Phase 1 included subjects pooled from the JS, RS and AUT series and, after 
quality control screening, consisted of 843 AD and 1,264 non-AD subjects.  Average 
ages of AD and non-AD individuals were 74.3 (SD = 4.5) and 72.4 (SD = 4.6) years, 
respectively.  In the event that a cholesterol-associated SNP from GWAS was not 
available by using this platform an appropriate proxy SNP was selected using 
SNAPproxy, a HapMap based proxy search 
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(http://www.broadinstitute.org/mpg/snap/; [312]).  Phase 2 consisted of 1,097 AD 
and 2,261 non-AD subjects pooled from the JS, RS and AUT series with average 
ages of 80.2 (SD = 7.9) and 82.4 (SD = 5.6) years, respectively. 
Phase 1 samples were genotyped by using HumanHap300-Duo Genotyping 
BeadChips processed with an Illumina BeadLab station (Illumina, San Diego, CA) at 
the Mayo Clinic Genotyping Shared Resource center (Rochester, MN).  Phase 2 
samples were genotyped by using SEQUENOM MassARRAY iPLEX Platform 
(Sequenom, San Diego, CA).  All samples were subject to strict quality control 
including elimination of samples with call rates < 90%, MAF < 0.01, H-W p < 0.001, 
discrepancy between reported and genotyped sex, cryptic relatedness and 
discordance upon visual inspection of genotype clusters.   
 
AD Association Testing 
 
Association testing for Phase 1 was performed using PLINK software to 
generate odds ratios (OR)s, 95% confidence intervals (CI)s and uncorrected p-
values based on additive logistic regression models 
(http://pngu.mgh.harvard.edu/purcell/plink) [313].  Of the eighteen cholesterol-
associated SNPs we identified in GWAS literature, rs157580 was considered to be a 
positive control for association with AD and thus was not considered regarding the 
number of tests performed.  The overall association between these seventeen SNPs 
and AD was tested for global significance using multivariable logistic regression. 
Phase 2 AD-SNP association testing was performed by using three SNPs 
identified in Phase 1 that were nominally associated or trended with AD (p < 0.1) and 
that had also been reported as having an association with gene regulation [186, 276-
278].  PLINK software was again used to generate additive logistic regression 
models for SNP-AD association testing.   
For phase 3, we maximized statistical power by testing for association 
between AD and rs3846662, rs1532085 or rs7298565 in the Phase 1 and Phase 2 
populations combined.  Association testing was done using additive logistic 
regression models generated in PLINK.  Rs3846662 and rs1532085 were also 
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tested for their effect on AD age-of-onset using Cox regression models in SPSS 
software (IBM, Somers, NY).  For each SNP, genotypes with similar effects were 
combined and tested against the third genotype for association with AD age-of onset 
using SPSS software. 
With a total of ~2,000 AD cases and ~4,000 non-AD controls, we have greater 
than 80% power to detect an association between AD and rs3846662 or rs1532085.  
Power calculations were performed by using the method developed by Purcell S et al. 
(http://pngu.mgh.harvard.edu/~purcell/gpc/cc2.html) [314]. 
 
Human Tissue 
 
Human brain tissue from the anterior cingulate was generously provided by 
the Sanders-Brown Alzheimer’s Disease Center Neuropathology Core and have 
been described elsewhere [315].  The samples were from deceased individuals with 
an average age at death of 82.4 ± 8.7 (mean ± SD) years for non-AD and 81.7 ±6.2 
years for AD subjects.  The average postmortem interval (PMI) for non-AD and AD 
subjects was 2.8 ± 0.8 and 3.4 ± 0.6 hours, respectively.  Non-AD and AD samples 
were comprised of 48% and 55% female subjects.  MMSE scores were, on average, 
28.4 ± 1.6 for non-AD subjects and 11.9 ± 8.0 for AD subjects. 
Human liver samples were obtained from the Brain and Tissue Bank for 
Developmental Disorders (Baltimore, MD) and have been previously described [316].  
The samples were from deceased individuals with an average overall age at death 
of 26.9 ± 9.0 years of age.  The average age at death was similar for women (27.3 ± 
8.5 years, n = 17) and for men (26.6 ± 9.4 years, n = 23).  The average PMI for 
women was 12.9 ± 4.5 hours while the average PMI for men was 10.0 ± 3.0 hours.  
 
Evaluation of rs3846662 effect on HMGCR exon 13 splicing efficiency in vivo  
 
To evaluate the association between rs3846662 and HMGCR exon 13 
splicing in human brain and liver tissue, genomic DNA and RNA were prepared from 
human tissue samples; cDNA was then reverse transcribed as reported previously 
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[316, 317].  Isoform specific primers were designed to amplify either HMGCR that 
contains exon 13 (HMGCR_FL) or lacks exon 13 (HMGCR∆13).  To accomplish this 
we designed a forward primer specific to HMGCR exon 12 (5’-
TGAGCGTGGTGTATCTATTCG-3’) and reverse primers specific to either HMGCR 
exon 13 (5’-GGCCACAAGACAACCTTCTG-3’) or the junction of HMGCR exons 12 
and 14 (5’-CCTCCACCAAGCAAGGAGTA-3’) to amplify HMGCR_FL and 
HMGCR∆13, respectively. 
Quantitative real-time PCR was performed on an MJ Opticon 4 thermal cycler 
(Biorad, Hercules, CA) by using 20ng of subject cDNA together with 10µl of SYBR 
green reagent (Quanta Biosciences, Gaithersburg, MD), 10µl of H2O and forward 
and reverse primers, each at 1 µM final concentration.  Cycling conditions consisted 
of a 3 minute denaturation step at 95°C followed by 40 cycles of denaturation for 15 
seconds at 95°C and annealing/extension for 45 seconds at 60°C.  A final melting 
curve was used to assess amplification fidelity in conjunction with subsequent 
inspection of PCR products on 8% TBE-PAGE gel (Sigma) stained with SYBR gold 
(Invitrogen, Carlsbad, CA).  Standard curves were generated from purified PCR 
products that were quantified by A260 before serial dilution.  Standard curves were 
then used to calculate copy numbers for each HMGCR isoform being measured.  
HMGCR expression was normalized to the geometric mean of HPRT and RPL32 
expression as described previously [318-320].  
 
Immunofluorescent staining of HMGCR 
 
Paraffin-embedded blocks of human anterior cingulate were sliced at a 
thickness of 5µm.  Sections were fixed to glass slides prior to deparaffinization in a 
series of xylene/EtOH/H2O.  Deparaffinized sections then submersed in pH 6 citrate 
buffer containing emulsifiers (Cell Marque, Cat # CMX633) and subject to antigen 
retrieval in a decloaking chamber (Biocare Medical, Cat # DC2002) for 30 min at 
80C then by 10 min at 75C.  Following antigen retrieval, slides were rinsed with H2O 
and then 1x TBS (pH 7.4) before blocking with 5% goat serum in 1x TBS for one 
hour.  Slides were then rinsed again with 1xTBS prior to incubation with rabbit α-
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HMGCR (1:25 dilution, Millipore Cat. # 07-457, Lot # 28743) and either mouse α-
MAP2 (1:100 dilution, Sigma) or mouse α-GFAP (1:25 dilution, ICN Biomedicals, Cat 
# 691102) in a solution of 2% goat serum (Sigma, Cat #G6767) overnight at 4°C.  
Slides were rinsed with 1xTBS and then treated with Alexa Fluor 488 goat α-mouse 
(Mol. Probes, Cat # 11029) and Alexa Fluor 568 goat α-rabbit (Mol. Probes, Cat # 
11036) secondary antibodies (1:200 dilution) in 0.15% goat serum and 1x TBS for 
one hour at room temperature.  Labeled slides were then washed in 1xTBS before 
treatment with Autofluorescence Eliminator Reagent (Chemicon, Cat # 2160) per the 
manufacturer’s instructions.  Slides were mounted using an anti-fading solution 
containing DAPI (Vectashield, Cat # H-1200), coverslipped, and visualized on a 
Nikon Diaphot fluorescence microscope.  
 
In-vitro minigene studies 
 
HMGCR exon 12-14 mini-gene vectors harboring either the A or G allele of 
rs3846662 were a kind gift of Dr. Jan L. Breslow (The Rockefeller University) and 
have been previously described [277].  The sequence of the HMGCR inserts differs 
only at rs3846662 (A/G). 
H4 human neuroglioma cells were maintained in Opti-MEM (Invitrogen) 
supplemented with a final concentration of 10% fetal bovine serum (FBS), 50 U/ml 
penicillin and 50μg/ml streptomycin (P/S).  HepG2 human hepatocellular carcinoma 
cells were grown in DMEM (Invitrogen) supplemented with a final concentration of 
10% FBS and 1% P/S.  Both cell lines were incubated at 37°C in a humidified 5% 
CO2 environment. 
Both H4 and HepG2 cells were seeded in 6-well plates (2x105 cells/well) 
containing either antibiotic-free Opti-MEM or DMEM media and 10% FBS, 
respectively.  Cells were allowed to grow for 24 hours prior to transfection with 1µg 
of either allele-specific HMGCR mini-gene vector in 6µl of FuGENE6 reagent (Roche 
Applied Sciences, Switzerland) and 94 µl of Opti-MEM (for H4 cells) or DMEM (for 
HepG2 cells), per the manufacturer’s recommendations.  Total RNA was prepared 
from cells twenty-four hours after transfection (RNeasy Mini Kit, QIAGEN) and 
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quantified at A260 before being reverse transcribed using random hexamers per the 
manufacture’s directions (SuperScript III, Invitrogen).  Transfections were performed 
in triplicate for each allele. 
Conventional PCR amplification of cDNA transcripts from HMGCR mini-genes 
was used to assess the splicing efficiency of HMGCR exon 13 in vitro as a function 
of rs3846662.  A reverse primer specific to HMGCR exon 14 (5’-
AGTGCTGTCAAATGCCTCCT-3’) and a forward primer specific to the expressed, 
upstream portion of the pSPL3 exon-trapping vector (5’-
TCTGAGTCACCTGGACAACC-3’) were used to amplify vector-derived HMGCR_FL 
and HMGCR∆13.  Amplification was performed for 32 cycles following an initial 
denaturation at 95°C for 5 minutes followed by cycling of 95°C denaturation for 30 
seconds, 60°C annealing for 30 seconds and 72°C extension for 1 minute, with a 
final extension at 72°C for 2 minutes.  PCR products were resolved using 8% TBE-
PAGE gel electrophoresis and visualized following staining with SYBR-gold and 
fluorescent image capture (Fuji FLA2000).  Vector-derived HMGCR_FL and 
HMGCR∆13 were identified by size and confirmed by sequencing (Davis 
Sequencing, Davis, CA).  The amounts of HMGCR_FL and HMGCR∆13 were 
quantified by fluorescent densitometry, corrected for background and normalized for 
size as described previously [318].  The ratios of HMGCR_FL and HMGCR∆13 for 
each transfection were then calculated to assess splicing efficiency and analyzed for 
their association with rs3846662 by using a paired Student’s t-test for each 
transfection experiment.   
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CHAPTER THREE 
 
RHEUMATOID ARTHRITIS-ASSOCIATED POLYMORPHISMS ARE NOT 
PROTECTIVE AGAINST ALZHEIMER’S DISEASE 
 
 
Background 
 
There is a long-standing, inverse relationship between the prevalence of 
Alzheimer’s disease (AD) and of rheumatoid arthritis (RA).  Jenkinson and 
colleagues first described the decreased prevalence of RA in patients suffering from 
senile dementia of the Alzheimer’s type as compared to cognitively intact individuals 
[321].  Further retrospective studies of clinical and autopsy data revealed that 
patients with RA exhibit a reduced prevalence of AD [322].  A study by Myllykangas-
Luosujarvi and colleagues evaluating AD pathology in patients with and without RA 
revealed that AD-associated neuropathology occurred four times less often in 
patients with RA as compared to the general population [323]. 
 The basis of this inverse relationship is unclear but may include both genetic 
and environmental factors.  RA and AD each have a strong genetic component, i.e., 
50% of RA risk and 60% of AD risk is attributable to genetic factors, supporting the 
original hypothesis of Jenkinson and colleagues that genetics might explain the 
relationship between AD and RA [324, 325].  Alternatively, anti-inflammatory 
medications used therapeutically for the treatment of RA could decrease AD risk by 
reducing AD-associated inflammation or via other mechanisms, .e.g., modulation of 
APP processing [326, 327].  Supporting this possibility, an initial double-blind, 
placebo-controlled study by Rogers et al. provided evidence that indomethacin 
slowed cognitive decline in patients with AD relative to placebo [328].  These 
findings were further supported by Breitner and colleagues who found that multiple 
anti-inflammatory medications slow disease progression and delay disease onset 
[329].  However, there has been little success replicating these findings in larger, 
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randomized clinical trials [330-333].  Hence, whether anti-inflammatory agents delay 
the onset of AD remains unclear.   
The recent advent of RA genome wide association studies (GWAS) has 
identified single nucleotide polymorphisms (SNP)s associated with RA that provide a 
foundation for evaluating the initial hypothesis of Jenkinson et al. that genetic 
variants that increase the risk of RA also decrease the risk of AD.  To this end, we 
tested whether seventeen RA-associated SNPs with genome-wide significance were 
associated with AD in a two-stage analysis using separate AD case-control 
populations.  We found that none of the seventeen alleles associated with increased 
RA risk were also associated with reduced AD risk.  Rather, we found three RA-
associated SNPs that were nominally associated with AD (p < 0.05).  One of these 
SNPs, rs2837960, was found to be significantly associated with AD in a combined 
analysis of our Stage 1 and Stage 2 populations when the Stage 2 population was 
restricted to individuals of similar age as Stage 1.  The gene closest to rs2837960 is 
BACE2, the product of which has been implicated in amyloid protein precursor 
(APP) processing [334, 335].  When we evaluated the expression of BACE2 
isoforms as a function of rs2837960, we found a trend for BACE2 expression with 
rs2837960.  In summary, genetic variants that increase RA risk do not decrease AD 
risk.  The inverse relationship between RA and AD may thus be better explained by 
environmental factors such as the use of anti-inflammatory medications.  Further 
functional investigation of rs2837960 is needed to elucidate the mechanism by which 
this SNP may modulate AD and RA. 
 
Results 
 
RA-associated SNPs are generally not associated with AD 
  
To evaluate whether RA-associated SNPs are also associated with AD, we began 
by identifying SNPs that are robustly associated with RA risk and then evaluated 
these SNPs for their association with AD in an exploratory Stage 1 case-control 
population of ~800 AD and ~1200 non-AD individuals.  Contrary to the hypothesis 
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that alleles associated with increased RA risk are also associated with reduced AD 
risk, only three of the seventeen RA-associated SNPs in our Stage 1 study were 
nominally significant for association with AD (p < 0.05, Table 1).  Moreover, for each 
these SNPs, the allele associated with increased RA risk was also associated with 
increased AD risk, further refuting the hypothesis that genetics underlies the inverse 
epidemiologic relationship between RA and AD prevalence.  The AD-associated 
SNPs are located in or near the genes BACE2 (rs2837960; p=0.002, OR = 1.29), 
TRAF1/C5 (rs3761847; p=0.006, OR = 1.19) and SALL3 (rs2002842; p=0.04, OR = 
1.15).  When a Bonferroni correction for multiple testing was applied to minimize 
false-positive associations between RA-associated SNPs and AD, only rs2837960 
exhibited a significant association with AD (p=0.03).  Furthermore, rs2837960 
remained significantly associated with AD after correcting for age, sex and APOE 
genotype per logistic regression (p = 0.012 OR = 1.26, Table 2).  Rs3761847 
remained significant following correction of Stage 1 analysis for covariates (p = 
0.007 OR = 1.21). 
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CHR SNP LOCUS RA 
OR 
RA  
P-value 
AD  
OR [96% CI] 
AD  
P-value 
21 rs2837960 BACE2 1.05  2x10-6 1.29 [1.10-1.52] 0.002 
9 rs3761847 TRAF1, C5 1.32 4x10-14 1.19 [1.05-1.35] 0.006 
18 rs2002842 SALL3 1.61  6x10-6 1.15 [1.01-1.31] 0.04 
9 rs881375 TRAF1, C5 NR 4x10-8 1.11 [0.97-1.26] 0.12 
6 rs660895 HLA-DRB1 3.62 1x10-108 0.93 [0.80-1.09] 0.39 
12 rs3184504 SH2B3 0.92 6x10-6 0.95 [0.84-1.08] 0.41 
8 rs2736340 BLK 1.19 6x10-9 0.95 [0.82-1.10] 0.47 
2 rs13031237 REL 1.13 8x10-7 1.04 [0.92-1.19] 0.52 
6 rs6457617 HLA-E 2.36 5x10-75 1.03 [0.91-1.17] 0.61 
4 rs13119723 IL2, IL21 1.12 7x10-7 0.96 [0.80-1.14] 0.62 
2 rs13017599 REL 1.21 2x10-12 1.03 [0.90-1.17] 0.67 
9 rs951005 CCL21 0.81 4x10-10 1.03 [0.87-1.22] 0.73 
6 rs6910071 HLA-DRB1 2.88 1x10-299 0.98 [0.84-1.14] 0.75 
1 rs2476601 PTPN22 1.94 9x10-74 1.03 [0.84-1.27] 0.77 
7 rs10488631 IRF5 1.19 4x10-11 0.99 [0.81-1.20] 0.91 
2 rs231735 CTLA4 0.83 6x10-9 1.01 [0.89-1.14] 0.91 
1 rs3890745 TNFRSF14 0.88 4x10-6 0.99 [0.87-1.13] 0.93 
 
Table 3.1  Stage 1 Analysis of RA-SNP’s Association with AD.  Seventeen SNPs 
exhibiting genome-wide significant associations with RA were tested for their 
association with AD risk using allelic models in a Mayo Clinic AD GWAS series of 
843 AD and 1264 non-AD individuals.  Three of the seventeen RA-associated SNPs 
were nominally associated with AD (p < 0.05).  Multiple testing was addressed by 
applying a Bonferroni (BF) correction for the number of tests performed.  The only 
SNP that retained significance after BF correction was rs2837960 (p = 0.03).  NR = 
value not reported in initial study. 
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CHR SNP OR L95 U95 P 
9 rs3761847 1.211 1.054 1.392 0.007 
21 rs2837960 1.256 1.051 1.502 0.012 
18 rs2002842 1.147 0.995 1.323 0.059 
9 rs881375 1.125 0.973 1.300 0.111 
6 rs660895 0.903 0.759 1.076 0.254 
8 rs2736340 0.920 0.786 1.077 0.298 
2 rs13031237 1.067 0.926 1.230 0.372 
6 rs6457617 1.056 0.921 1.211 0.435 
2 rs13017599 1.055 0.914 1.217 0.467 
9 rs951005 1.060 0.880 1.278 0.539 
6 rs6910071 0.949 0.797 1.130 0.558 
2 rs231735 1.027 0.895 1.178 0.705 
7 rs10488631 0.961 0.774 1.193 0.717 
4 rs13119723 0.969 0.800 1.174 0.746 
1 rs3890745 1.022 0.882 1.186 0.770 
1 rs2476601 1.018 0.811 1.278 0.880 
12 rs3184504 0.998 0.869 1.146 0.976 
 
Table 3.2 Stage 1 Analysis of RA-SNP’s Association with AD Corrected for Age, 
Sex and APOE Genotype.  Using logistic regression, SNP-AD associations were 
corrected for the potential effects of age, sex and APOE genotype (all of which were 
independent predictors of AD in our Stage 1 analysis).  The minor alleles of both 
rs2837960 and rs3761847 were significantly associated with increased risk of AD (p 
< 0.05) while the minor allele of rs2002842 exhibited only a trend toward an 
increased risk of AD. 
 
Rs2837960 is significantly associated with AD in individuals less than 80 
years of age 
 
 The three RA- and potentially AD-associated SNPs from Stage 1 were 
evaluated further for their association with AD in a Stage 2 case-control series that 
consisted of 2677 non-AD and 1102 AD subjects.  Contrary to our initial results, 
these SNPs exhibited no association with AD in our Stage 2 population (Table 3).  
Correction for age, sex and APOE genotype had marginal, non-significant effects on 
the association between these three SNPs and AD.  Our Stage 1 and Stage 2 
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populations were combined with the intention of clarifying the overall association 
between these three SNPs and AD.  Analysis of this combined population, 
consisting of 3949 non-AD and 1965 AD subjects, suggested that rs2837960 is 
significantly associated with AD (p = 0.04, OR = 1.11, Table 4).  When these results 
were corrected for age, sex and APOE genotype this association between 
rs2837960 and AD showed only a trend (p = 0.14).   
 
CHR SNP   OR L95 U95 P 
      Uncorrected Regression   
21 rs2837960  1.011 0.887 1.153 0.865 18 rs2002842  0.992 0.896 1.099 0.880 9 rs3761847  0.921 0.832 1.019 0.112 
      Corrected Regression   
21 rs2837960 
 
1.000 0.867 1.154 0.997 
18 rs2002842 
 
0.990 0.886 1.106 0.857 
9 rs3761847 
 
0.905 0.809 1.012 0.080 
 
Table 3.3 Stage 2 Analysis of Top RA-SNPs Associated with AD.  No RA-
associated SNP that exhibited an association with AD in Stage 1 was found to 
exhibit an association with AD in our Stage 2 population.  This remained true when 
data were analyzed and corrected for covariates including age, sex and APOE 
genotype of Stage 2 individuals, who on average were significantly older than Stage 
1 individuals (p < 0.001, Students t-test). 
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CHR SNP   OR L95 U95 P 
      Uncorrected Regression   
21 rs2837960 
 
1.113 1.007 1.230 0.037 
18 rs2002842 
 
1.031 0.952 1.116 0.460 
9 rs3761847 
 
1.011 0.934 1.093 0.793 
      Corrected Regression   
21 rs2837960 
 
1.087 0.974 1.212 0.138 
18 rs2002842 
 
1.017 0.933 1.110 0.699 
9 rs3761847 
 
1.002 0.920 1.091 0.965 
 
Table 3.4. Combined Stage 1 and Stage 2 Analysis of Top RA-SNPs for 
Association with AD.  Initial analysis of combined Stage 1 and Stage 2 populations 
revealed that rs2837960 remained overall nominally significant for association with 
AD per logistic regression (p < 0.05).  When this analysis was repeated to include 
covariate data, rs2837960 showed only a trend for association with AD.   
 
Due to the large discrepancy in average age between our Stage 1 and Stage 
2 populations, and the possibility that the impact of genetic risk factors may decline 
with age, we next evaluated a subset of Stage 2 individuals that had an age of AD 
diagnosis between 60 and 80 years of age along with non-AD individuals with the 
same age range [50].  Thus, our age parameters and average population ages for 
Stage 2 mimicked those of Stage 1.  This effort resulted in a sample population that 
consisted of 186 AD (average age 73) and 912 non-AD individuals (average age of 
74).  This population showed a trend in the OR of rs2837960 that was consistent 
with that of the Stage 1 analysis (Table 5), i.e., the minor rs2837960_G allele 
appeared to impart an increased, although non-significant, risk of AD.  The SNPs 
rs3761847 and rs2002842, that were associated with AD in Stage 1, failed to show 
an association with AD in Stage 2.  We note that there was significant overlap in the 
95% confidence intervals between Stage 1 and Stage 2 for all three of these SNPs.  
Analysis of the combined data from Stage 1 and the Stage 2 subset revealed that 
only rs2837960 maintained a significant association with AD (p=0.002, OR =1.27, 
Table 6).  This association between rs2837960 and AD remained significant 
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following correction for the covariates age, sex and APOE (p=0.02, OR = 1.20).  
Thus, when the Stage 1 and Stage 2 populations were matched for age, rs2837960 
was significantly associated with AD risk. 
 
CHR SNP   OR L95 U95 P 
      Uncorrected Regression   
21 rs2837960 
 
1.218 0.922 1.609 0.165 
18 rs2002842 
 
1.002 0.802 1.253 0.983 
9 rs3761847 
 
0.897 0.723 1.113 0.324 
      Corrected Regression   
21 rs2837960 
 
1.225 0.903 1.664 0.192 
18 rs2002842 
 
1.013 0.794 1.292 0.920 
9 rs3761847 
 
0.878 0.694 1.110 0.278 
 
 
Table 3.5 Analysis of RA-SNP's Association with AD in Stage 2, Age-Matched 
to Stage 1.  The three RA-associated SNPs suggesting association with AD were 
tested further for their association with AD risk by using logistic in a series of 912 
non-AD and 186 AD individuals whose ages more closely resembled those of Stage 
1 individuals.  Although significant associations were not observed between these 
SNPs and AD, the results for each SNP were not significantly different from those 
obtained in Stage 1. 
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CHR SNP   OR L95 U95 P 
      Uncorrected Regression   
21 rs2837960 
 
1.239 1.083 1.418 0.002 
18 rs2002842 
 
1.056 0.948 1.178 0.323 
9 rs3761847 
 
1.090 0.981 1.210 0.108 
      Corrected Regression   
21 rs2837960 
 
1.199 1.032 1.392 0.018 
18 rs2002842 
 
1.050 0.931 1.184 0.430 
9 rs3761847 
 
1.075 0.958 1.207 0.217 
 
Table 3.6 Analysis of Top RA-SNPs for Association with AD in Combined 
Stage 1 and Age-Matched Stage 2.  Combined analysis of Stage 1 and Stage 2 
data from individuals between 60 and 80 years of age was performed to clarify the 
association of rs2837960, rs3761847 and rs2002842 with AD risk.  The only SNP 
found to retain a significant association with AD was rs2837960, the G allele of 
which appears to increase AD risk. 
 
In silico analyses suggest that rs2837960 is associated with BACE2 
expression and splicing 
 
 To gain insights into the possible actions of rs2837960, we first identified 
genes within the vicinity of rs2837960 by using HapMap [16].  This analysis found 
that rs2837960 resides within a haplotypic block that includes the promoter region 
and 5’-UTR of BACE2 (Figure 1A).  Due to the presence of distinct proximal and 
distal BACE2 promoters, and the potential contribution of upstream regulatory 
elements to BACE2 expression, we considered the possibility that rs3846662 may 
affect BACE2 expression [336-338].  We then queried whether there was an 
association between rs2837960 and BACE2 expression in human brain by using the 
SNPexpress database, which includes data from 93 human brain samples [339].  
This analysis revealed a trend towards increased BACE2 expression in rs2837960 
minor allele carriers (p = 0.08, Figure 1B).  Since these data suggest that rs2837960 
may modulate BACE2 expression and since BACE2 function in turn may modulate 
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AD and cognition, we hypothesized that rs2837960 modulates AD risk by altering 
BACE2 expression in the human brain [340-342]. 
 
 
Figure 3.1  Location of s2837960 and trend between rs2837960 and BACE2 
expression.  The gene nearest to rs2837960 is BACE2, whose transcription start 
site is ~27.8kb downstream.  (A) Analysis of the HapMap CEU population reveals 
that rs2837960 resides within a linkage disequilibrium block that includes the BACE2 
promoter region and first exon.  (B) Analysis of exon tiling array data within the 
SNPExpress database suggests a trend between rs3837960_G and increased 
BACE2 expression (p=0.08). 
 
Relationship between rs2837960 and BACE2 isoforms in the human brain 
 
 To pursue this hypothesis, we sought to directly quantify BACE2 isoforms as 
a function of rs2837960 in a series of human brain samples.  We began by 
confirming the presence of previously identified BACE2 isoforms that lack exons 
seven or eight (BACE2d7 and BACE2d8, respectively) as well as the full-length, 
nine-exon BACE2 transcript (BACE2_FL).  We also identified a novel isoform lacking 
both exons 7 and 8 (BACE2d7/8) that was confirmed by direct sequencing (Figure 2).  
Considering the biological relevance of these isoforms, we note that the loss of exon 
7 is predicted to result in an in-frame deletion of 50 amino acids, resulting in a 50.3 
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kDa peptide.  Moreover, the BACE2 protein found in human brain appears to 
correspond to the BACE2d7 isoform based upon its size and pattern of epitope 
reactivity [334].  In contrast, the loss of exon 8 or exons 7-8 results in a frameshift 
and prematurely truncated BACE2 proteins of 43.0 kDa and 37.5 kDa, respectively.  
Hence, we chose to use real-time PCR to quantify BACE2tot and BACE2d7 since 
they represent the expression of total BACE2 and functional BACE2, respectively.  A 
total of 53 brain cDNA samples were analyzed for genotypic associations between 
rs2837960 and expression of BACE2tot and BACEd7.  This effort revealed a trend 
between rs2837960 and the expression of BACE2tot (p = 0.07) and BACE2d7 (p = 
0.10, Figure 3).  It is noteworthy that the trend toward greater expression of 
BACE2tot and BACE2d7 in rs2837960 minor allele carriers in our results is similar to 
the results from SNPExpress. 
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Figure 3.2  BACE2 isoforms present in human brain.  Human brain cDNA 
samples were screened for BACE2 isoforms using conventional PCR amplification 
across the alternatively spliced regions of exons 7 and 8.  (A) Four alternatively 
spliced BACE2 isoforms were detected among multiple individuals.  (B) Direct 
sequencing of the resulting splice variants confirmed their identities as BACE2d7, 
BACE2d8 and BACE2d7/8.  Deletion of BACE2 exon 7 results in an in-frame 
deletion of 50 amino acids whereas deletions of BACE2 exon 8 or exons 7 and 8 
lead to frameshifts and premature truncation of the protein. 
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Figure 3.3  Quantification of BACE2tot and BACE2d7 in human brain.  Real-
time PCR with isoform-specific primers was used to quantify the expression of 
BACE2tot and BACE2d7 in cDNA prepared from human brain.  (A-B) Samples 
exhibit a trend toward increased expression of both BACE2tot and BACE2d7 in the 
presence of rs2837960_G (p = 0.07 and p = 0.10, respectively, using Jonckheere-
Terpstra testing). 
 
Discussion 
 
The primary finding of this investigation is that the majority of seventeen 
SNPs that exhibit a genome-wide significant association with RA are not associated 
with AD.  Furthermore, the minor allele of rs2837960, which was found to be 
significantly associated with AD risk after combined analysis of Stage 1 and age-
matched Stage 2 data, was associated with an increased risk of both RA and AD.  
Hence, these results contest the hypothesis that genetics underlie the inverse 
relationship between RA and AD, i.e. that alleles associated with an increased risk of 
RA are protective against AD.  A secondary finding is that we have pursued the role 
of rs2837960 in its possible regulation of the nearby BACE2 gene.  We report the 
presence of multiple BACE2 isoforms in human brain and that rs2837960 shows a 
trend for association with BACE2tot and BACE2d7, which represent total BACE2 
and functional BACE2, respectively [334].  In summary, the genetic underpinnings of 
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RA have negligible overlap with AD with the exception of rs2837960, which is 
associated with both RA and AD, possibly through its effects on BACE2 expression. 
RA and AD each have a strong genetic component that accounts for 
approximately 50% and 60% of their risk, respectively [324, 325].  The remainder of 
RA and AD risk is likely derived from environmental influences.  The vast majority of 
RA-associated SNPs implicate gene products involved in immune system processes.  
Chronic inflammation of the brain is a common feature of AD pathology, raising the 
possibility that RA-associated SNPs that influence immune system function could 
influence AD risk [343-345].  It is well established that some of the most strongly AD-
associated genes, including CLU, CR1, TNF and CCR2, exhibit ontological 
association with immune system processes [74, 346-353].  Hence, the impetus for 
pursuing genetic overlap between RA and AD is greater than that provided by their 
epidemiologic relationship alone.  However, our results indicate that RA-associated 
SNPs, which pertain largely to gene products involved in immune system processes, 
are not associated with AD.   
There are several possible interpretations of our primary findings.  The lack of 
overlap between RA-associated SNPs and AD could be due in part to the tissue-
specific expression of DNA and RNA binding proteins required to interact with these 
SNPs to manifest effects on gene expression [354].  However, if any of the 
seventeen RA-associated SNPs included in this study are capable of modulating 
peripheral immune system activity, either alone or in combination with each other, 
then it is probable that their peripheral effects on the immune system would indirectly 
affect immune system activity within the CNS.  Evidence supporting the ability of 
peripheral inflammation to modulate CNS inflammation has been reported previously 
[355].  Therefore, if RA-associated SNPs are only functional in the periphery then 
their effects on immune system function and inflammation should manifest in the 
CNS, even if the same SNPs do not modulate endogenous immune system function 
within the brain. 
What is yet unclear is whether RA-associated alleles actually propagate 
inflammation and, if so, why they would not be expected to increase, rather than 
decrease, AD risk.  In fact, the results of our study suggest that alleles that increase 
 63 
RA risk may likewise increase AD risk, i.e., rs2738960_G increases risk of both RA 
and AD, while rs3761847_G and rs2002842_A show a similar trend.  If these 
observations are replicated in future studies, alleles that are pro-inflammatory may 
emerge as risk factors for both RA and AD.  More explicitly, considering the role of 
genetics and environment in RA and AD, these results suggest that RA genetics 
alone may enhance rather than reduce AD risk.  Hence, the inverse epidemiologic 
relationship between RA and AD is likely explained by an environmental RA-
associated influence.  In this regard, McGeer et al. postulated that the reduced 
prevalence of AD in RA patients is related to the use of anti-inflammatory drugs for 
the treatment of RA [322].  Multiple studies of anti-inflammatory agents have since 
been performed to test for their ability to modify AD risk and cognitive decline in AD 
patients, yielding mixed results [328, 356-359].  To some extent, variability in study 
outcome may be explained by the additional ability of a subset of anti-inflammatory 
medications to reduce production of the neurotoxic Aβ1-42 peptide [326].  Further 
investigation is required to clarify the functional genetics of RA- and AD-associated 
SNPs and the role of anti-inflammatory medications in AD. 
In pursuit of the functional genetics of rs2837960, which is associated with an 
increased risk of RA and AD, we investigated its association with the expression of 
BACE2 isoforms in human brain [360].  Thus, our secondary finding is that the minor 
allele of rs2837960 showed a strong trend for association with increased expression 
of BACE2tot and BACE2d7, the latter of which may represent the majority of 
functional BACE2 in human brain [334]. BACE2 encodes a transmembrane aspartic 
protease and is ~75% homologous with BACE1 with regard to amino acid sequence 
[338].  Although the function of BACE2 is disputed, it appears to possess both β-
secretase and α-secretase-like activities [335].  Data obtained from the study of 
BACE1/BACE2 double-knockout mice suggest that BACE2 expressed in glia 
contributes significantly to Aβ production [361].  This glial-specific expression is likely 
due to the more distal of the two distinct BACE2 promoters, neither of which share 
similarity with the BACE1 promoter [336-338].  
Several factors are consistent with the possibility that rs2837960, or SNPs in 
tight linkage with rs2837960 (LD of r2 > 0.8), are functional in modulating BACE2 
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expression.  This evidence includes the observation that (i) rs2837960 resides within 
a haplotypic block that spans the region containing both the proximal and distal 
BACE2 promoters as well as the 5’UTR and first exon of BACE2, (ii) the region 
surrounding rs2837960 and its proxy SNPs (r2 = 1.0, ~4kb window) is well 
conserved in primates per rVISTA analysis (data not shown), and (iii) the alleles of 
rs2837960 and its proxy SNPs are predicted to differentially affect transcription 
factor binding per PROMO 3.0 analysis of the TRANSFAC database (data not 
shown) [362-364].  
Other studies that examined the association between BACE2 polymorphisms 
and AD risk have yielded mixed results [365-371].  These studies differ with our 
study in that (i) they have focused on SNPs much more proximal to BACE2 that are 
not in strong linkage disequilibrium with rs2837960 and (ii) they generally utilized 
smaller populations than those utilized in our present study.  Future analyses of the 
association between BACE2 SNPs and AD should therefore take into account SNPs 
that are more distal to BACE2, such as rs2837960, as well as utilize larger 
population sizes that are sufficiently powered to detect associations with AD.  Thus, 
in future studies rs2837960 may emerge as a risk factor for both RA and AD that 
functionally modulates BACE2 expression.  Elucidation of the precise mechanism by 
which rs2837960, or a SNP that is proxy to it, modulates BACE2 expression may 
contribute to a better understanding of the role of BACE2 in both AD and RA 
pathology. 
 
Conclusions 
 
In summary, we have provided evidence that RA genetics do not underlie the 
inverse relationship between RA and AD but rather may promote AD.  Furthermore, 
we have found that rs2837960 is associated with both RA and AD and that it, or one 
of its proxy SNPs, may modulate the expression of BACE2.  As we learn more about 
the pathologic processes behind both RA and AD, including the contribution of 
BACE2 to each disease, a greater understanding of the factors underlying the 
inverse relationship between these two diseases may be obtained. 
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Methods 
 
SNP Selection   
 
The Human Genome (HuGE) Navigator (http://www.hugenavigator.net) was 
queried using the search term “rheumatoid arthritis” to identify RA-associated SNPs 
of genome-wide significance [307].  Six available studies utilizing individuals of 
European decent were chosen to mimic the AD MAYO GWAS demographics (Table 
7).  Sample sizes ranged from ~1,600 (810 RA, 794 non-RA) to ~25,500 (7,322 RA, 
18,262 non-RA).  Thus, we identified twenty-eight candidate SNPs for study from the 
literature.  SNPs which appeared more than once or that were in tight linkage 
disequilibrium with each other, i.e. r2 > 0.8 (according to the CEU HapMap 
population), were considered to be redundant and only those with the lowest RA-
associated p-value were retained for further analysis [16].  This effort reduced the 
number of candidate SNPs to twenty-two.  If a candidate RA-associated SNP was 
not available within the Mayo Clinic AD GWAS, an appropriate proxy SNP (LD of r2 > 
0.8) was selected by using the HapMap-based SNAP proxy search 
(http://www.broadinstitute.org/mpg/snap/) [312].  Ultimately, seventeen of the 
candidate SNPs or their proxies were present in our AD GWAS dataset. 
  
 66 
 
Article PMID # of GWAS Hits 
Gregersen et al., Nat Genet, 2009 19503088 5 
Raychaudhuri et al., Nat Genet, 2008 18794853 9 
Julia et al., Arthritis Rheum, 2008 18668548 2 
WTCCC, Nature, 2007 17554300 7 
Plenge et al., N Engl J Med, 2007 17804836 3 
Plenge et al., Nat Genet, 2007 17982456 2 
 
Table 3.7  RA GWAS reports identifying RA genetic risk factors.  Six RA GWAS 
manuscripts were identified by querying the HuGE Navigator database for 
“rheumatoid arthritis.”  Together, these studies document twenty-eight SNPs that are 
significantly associated with RA, p < 10-6.  Of these twenty-eight SNPs, seventeen 
(or their proxies) were present in our AD GWAS and evaluated further for their 
association with AD. 
 
Case and Control Samples 
 
The Mayo Clinic case-control samples used for the Stage 1 analysis have 
been described in detail in a prior GWAS publication [311].  The Mayo Clinic case-
control series used for the Stage 2 study have also been previously described [310].  
Briefly, clinical diagnoses of probable AD were made according to NINCDS-ADRDA 
criteria for samples from Jacksonville, FL (JS) and Rochester, MN (RS); age-
matched controls had a score of 0 on the Clinical Dementia Rating scale.  Additional 
samples were obtained from the Mayo Clinic brain bank (AUT); autopsy-confirmed 
diagnosis of AD (NINCDS-ADRDA, Braak score >4.0) was utilized for AD samples 
while non-AD samples exhibited limited AD pathology (Braak <2.5, not including 
other unrelated pathology). 
 
AD Association Testing 
 
Association testing of RA-associated SNPs for AD risk was carried out in two 
stages by using PLINK software (http://pngu.mgh.harvard.edu/purcell/plink/) [313].  
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All genotyped samples were subject to strict quality control including elimination of 
samples with call rates < 90%, MAF < 0.01, HW p < 0.001, discrepancy between 
reported and genotyped sex, cryptic relatedness and discordant genotype clustering.  
Stage 1 consisted of 1264 non-AD and 843 AD subjects with average ages of 74.3 ± 
4.5 (age at last assessment, mean ± SD) and 72.4 ± 4.6 years (age at diagnosis), 
respectively.  The non-AD and AD groups in this series consisted of 51.7% and 
57.5% female individuals, respectively.  Stage 1 samples were genotyped by using 
HumanHap300-Duo Genotyping BeadChips processed with an Illumina BeadLab 
station (Illumina, San Diego, CA) at the Mayo Clinic Genotyping Shared Resource 
center (Rochester, MN).  
We proceeded to test for an association between the seventeen RA-
associated SNPs and AD in this Stage 1 case-control population.  Stage 1 
association testing was performed by using PLINK to generate allelic models that 
included odds ratios (OR), 95% confidence intervals (CI)s and uncorrected p-values.  
Logistic regression was also performed using the covariates age, sex and APOE 
genotype.  With regards to multiple testing we expected to obtain approximately one 
false positive result given α = 0.05 (seventeen unique SNPs; 17 tests x 0.05 = 0.85).  
Bonferroni correction for multiple testing was also applied to data generated using 
allelic models. 
Stage 2 samples were genotyped by using SEQUENOM MassARRAY iPLEX 
Platform (Sequenom, San Diego, CA).  Overall, Stage 2 consisted of 2677 non-AD 
and 1102 AD subjects with average ages of 81.0 ± 6.2 and 83.5 ± 6.6 years of age, 
respectively.  The non-AD and AD groups were composed of 55.0% and 64.0% 
female individuals, respectively.  Stage 2 AD-SNP association testing was 
performed using only the three SNPs identified in Stage 1 as being associated with 
both RA and AD.  PLINK software was used to generate odds ratios, 95% CIs and p-
values per allelic modeling.  Logistic regression including the covariates age, sex 
and APOE genotype was also performed.  To evaluate the overall significance of 
Stage 1 and 2 data, they were combined and examined collectively. 
Due to the considerable difference in mean age between Stage 1 and Stage 2 
individuals, and due to our interest in focusing on genetic, rather than environmental 
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factors, we also chose to examine only Stage 2 individuals between 60 and 80 years 
of age.  Hence, when Stage 2 was limited to individuals between 60 and 80 years of 
age, our analysis included 912 non-AD and 186 AD subjects with average ages of 
73.9  ± 3.8 and 72.8 ± 5.1 years.  The non-AD and AD groups consisted of 49.9% 
and 57.0% female individuals, respectively.  Similar to our analysis of our initial 
Stage 2 population, logistic regression of this modified Stage 2 population was also 
performed to test for an association between the three AD-associated SNPs from 
Stage 1.  Furthermore, we evaluated the overall significance of RA-associated SNP 
associations with AD in combined Stage 1 and Stage 2 individuals between 60 and 
80 years of age. 
 
Human Tissue 
 
Human anterior cingulate brain specimens were generously provided by the 
Sanders-Brown AD Center Neuropathology Core and have been described 
elsewhere [315].  The samples were from deceased individuals with an average age 
at death for females of 82 ± 7 years (mean ± SD, n = 29) and for males of 81 ± 8 (n 
= 24).  The average postmortem interval (PMI) for females and males was 3.2 ± 0.8 
h and 3.0 ± 0.8 h, respectively. 
 
Evaluation of BACE2 isoforms in vivo  
 
To gain insights into the functionality of rs2837960 we tested for an 
association between rs2837960 and BACE2 expression in human brain.  We first 
screened anterior cingulate samples for the presence of BACE2 and its known 
alternatively spliced isoforms that lack exons 7 and 8, respectively.  Total RNA and 
genomic DNA were prepared from human tissue samples; the RNA was reverse 
transcribed as we have reported elsewhere [316, 317].  Conventional PCR using 
Platinum Taq (Invitrogen, Carlsbad, CA) was used to amplify the region of BACE2 
spanning exons 6-9 (Table 8).  Thermal cycling conditions consisted of denaturation 
at 95°C for 5 min followed by 32 cycles of 95°C for 30 s, 60°C for 30 s, 72°C for 1 
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min and a final extension at 72°C for 2 min.  PCR products were separated using 8% 
TBE-PAGE gel electrophoresis and visualized using SYBR-gold fluorescent stain 
(Invitrogen) and a fluorescence imager (FLA-2000, Fuji).  To confirm the identities of 
the BACE2 splice variants, bands were excised, purified and directly sequenced 
(Davis Sequencing, Davis, CA). 
 
BACE2 Isoform screening primers   
BACE2  Exon 6 Forward: ATAACGCAGACAAGGCCATC 
BACE2  Exon 9 Reverse: GGACACAGTTGCTGGCTACA 
BACE2 RT-PCR primers   
BACE2  Exon 6 Forward:  GCCCCAGAAGGTGTTTGAT 
BACE2  Exon 6-8 Junction Reverse: GGCTGAATGTAAAGCAGAG 
BACE2  Exon 5 Forward:  TGGGTGGAATTGAACCAAGT 
BACE2  Exon 6 Reverse:  GATGGCCTTGTCTGCGTTAT 
 
Table 3.8.  Primers used for analyses of BACE2 isoform expression. 
 
To quantify total BACE2 expression (BACE2tot) and expression of the 
BACE2 isoform lacking exon 7 (BACE2d7) we designed separate primer sets.  
BACE2tot expression was measured by amplification of a product spanning a non-
alternatively spliced region of BACE2 (exons 5-6).  Isoform-specific primers 
designed to amplify BACE2d7 consisted of a forward primer specific to BACE2 exon 
6 and a reverse primer specific to the junction of exons 6-8 (Table 8).  DNA samples 
were genotyped using a TaqMan SNP Genotyping Assay (ID # C_2688271_10; ABI, 
Carlsbad, CA). 
Quantitative real-time PCR reactions contained ~20ng of sample cDNA 
together with 10µl of PerfeCTA SYBR green SuperMix (Quanta Biosciences, 
Gaithersburg, MD), 10µl of ddH2O and 20 pmol of forward and reverse primers.  
Cycling conditions included a 3 minute denaturation step at 95°C followed by 40 
cycles of denaturation for 15 seconds at 95°C and annealing/extension for 45 
seconds at 60°C using an MJ Opticon 4 thermal cycler (Biorad, Hercules, CA).  A 
melting curve was generated following cycling to assess the purity of amplification 
product.  Fidelity of amplification was also assessed via visual inspection of PCR 
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products on 8% TBE-PAGE gel stained with SYBR gold.  Standard curves were 
generated from purified PCR products that were quantified by A260/280 
spectrophotometric analysis.  Standard curves were then used to calculate the copy 
number for each BACE2 isoform measured. 
Hypoxanthine-guanine phosphoribosyltransferase (HPRT) and ribosomal 
protein L32 (RPL32) were used as housekeeping genes per the analysis of geNorm 
software as described previously [318-320].  Expression levels of each of these 
genes were measured by using quantitative real-time PCR and gene specific 
primers under conditions identical to cycling conditions for BACE2.  Standard curves 
were used to generate exact copy numbers, which in turn were used to calculate the 
sample-specific geometric mean of HPRT and RPL32 expression.  The geometric 
mean was in turn used to normalize subsequent BACE2 expression data.  Analysis 
of the association between BACE2 isoforms and rs2837960 genotype was 
performed using non-parametric Jonckheere-Terpstra testing (PASW Statistics, v.18, 
IBM, Somers, NY). 
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CHAPTER FOUR 
 
DIABETES, SINGLE NUCLEOTIDE POLYMORPHISMS AND THE RISK OF 
ALZHEIMERS DISEASE 
 
 
Background 
 
 Diabetes mellitus (DM) and Alzheimer’s disease (AD) are each expected to 
reach epidemic proportions in twenty-first century.  Although each condition is 
ranked among the ten most common causes of death in the United States, the 
comorbid status of these conditions is remains controversial.  Analysis of longitudinal, 
multi-ethnic, population-based studies suggests that DM is associated with an 
overall increase in dementia, and particularly AD [372, 373].  Similarly, meta-
analysis suggests that a diagnosis of DM is associated with an increased incidence 
of AD (Hazard ratio 1.52, 95% CI 1.31-1.73) [374].  This is in contrast to earlier 
studies using AD-based populations that suggested an inverse relationship between 
DM and AD [375, 376].  However, more recent data suggest that DM may be 
present in the majority of AD patients [377]. 
Symptomatically, cognitive decline tends to be accelerated in elderly patients 
with DM, although the extent of this phenomenon varies [378, 379].  
Neuropsychological testing data suggest that patients with DM are at increased risk 
for impairments in learning and memory [380, 381].  Additionally, patients with DM 
exhibit accelerated cortical atrophy and pathologic microvascular changes such as 
cerebral amyloid angiopathy [382-384].  Thus, patients with DM tend to exhibit 
similar neuropsychiatric signs and symptoms as patients with late-onset AD. 
Multiple theories have been proposed to mechanistically explain how DM or 
related traits could increase AD risk, however no outstanding etiology has been 
identified.  The roles of vascular risk factors, hyperglycemic neurotoxicity, insulin 
signaling, insulin therapy and other medications have been studied in regards to 
their relationship with AD [372, 385, 386].  Few studies have taken these potential 
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confounders into account when examining the relationship between DM and AD 
[372].  A study by Kivipelto et al. yielded observations that obesity, a major risk 
factor for type 2 DM (T2DM), is associated with dementia [386].  The incidence of 
AD was even higher in individuals who also had high cholesterol and elevated blood 
pressure, illustrating the potential contribution of metabolic syndrome to AD risk.  At 
the cellular and molecular level it has been proposed that disruption of energy 
metabolism, propagated by glycemic dysregulation, may lead to neurotoxicity and 
cognitive decline [385]. 
The potential for shared genetic predisposition to both DM and AD is unclear.  
Data suggest that the presence of both DM and the APOEε4 allele increase the risk 
of dementia two-fold compared to the effects of DM or APOEε4 in isolation [384, 
387].  Several genes implicated in DM have been associated with AD via GWAS or 
gene-expression array studies.  For example, expression of PGC-1α (peroxisome 
proliferator-activated receptor γ coactivator 1α) is decreased in the AD brain and can 
mitigate hypoglycemia-induced increases in the production of β-amyloid [388].  
SORCS1 (a member of the sortilin family of vacuolar protein sorting proteins), which 
is associated with both AD and DM risk, also appears to play a role in the regulation 
of both β-amyloid metabolism and glucose metabolism [389].  Per genome-wide 
association studies (GWAS), variants in or near IDE (insulin-degrading enzyme) are 
also associated with both DM and AD, as alterations in plasma Aβ1-40 [390-393]. 
The objective of this study is to evaluate the broad contribution of DM-
associated genetic variants to AD risk and thus expand our knowledge of genetic 
overlap of DM and AD.  GWAS have identified more than 200 SNPs associated with 
type 1 DM (T1DM), T2DM and DM-related traits. Thus, with the intention to elucidate 
potential mechanisms by which DM propagates AD risk, we have tested the 
association between DM-associated SNPs from GWAS and AD.  Little overlap was 
observed between SNPs associated with DM or DM-related traits and AD in our 
elderly case-control population.  The SNPs rs7804356, located in the gene SKAP2 
(src kinase associated phosphoprotein 2), and rs2237892, located in the gene 
KCNQ1 (potassium voltage-gated channel, KQT-like subfamily, member 1), are 
nominally associated with AD (p < 0.05).  Rs7804356 is also associated with the 
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inclusion of a rare SKAP2 exon, per the SNPExpress database, however presence 
of this rare exon was not detectable in our human brain samples.  In conclusion, 
DM-associated SNPs contribute little to AD risk although nominal associations 
between the loci SKAP2 and KCNQ1 with AD may provide novel insight into AD 
pathogenesis. 
 
Results 
 
The T1DM-associated SNP rs7804356 is nominally associated with AD 
 
We identified a total of eighty-six reported associations between SNPs and 
T1DM in the HuGE Navigator database.  These reports consisted of sixty-seven 
individual SNPs, several of which were reported in more than one study.  Pairwise 
linkage disequilibrium using SNAP Proxy was used to eliminate SNPs with an LD of 
r2 ≥ 0.8, such that only the more significantly T1DM-associated SNP was retained.  
This yielded sixty-seven unlinked SNPs, each demonstrating an association with 
T1DM (p > 1x10-6).  Of these SNPs, a total of thirty (or their proxies) were present in 
our AD case-control population. 
Testing for association between these thirty SNPs and AD was performed 
using PLINK.  Four separate models were used to test for association with the 
intention of exploring the dataset without initial considerations for multiple testing.  
The Cochran-Armitage model suggested that at least one of the thirty SNPs tested, 
rs7804356 (SKAP2), exhibits a nominally significant trend with AD (p = 0.03).  
Genotypic and dominant models also further implicate SKAP2 as being significantly 
associated with AD (p = 0.02 and 0.01, respectively).  Additional, non-significant 
trends were identified between both rs4505848 (KIAA1109) and rs4505848 
(VN1R55P/RNLS) using the Cochran-Armitage model with regard to AD (p ≤ 0.1).  
Likewise, several non-significant associations between T1DM-associated SNPs and 
AD were suggested per genotypic, dominant and recessive models. 
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CHR SNP ID TEST AFF UNAFF P GENE 
7 rs7804356 TREND 381/1301 636/1858 0.03 SKAP2 
4 rs4505848 TREND 546/1126 876/1612 0.09 KIAA1109 
10 rs10509540 TREND 467/1197 641/1853 0.09 VN1R55P/RNLS 
              
7 rs7804356 GENO 47/287/507 69/498/680 0.02 SKAP2 
12 rs3764021 GENO 191/393/258 268/646/338 0.07 CLEC2D 
              
7 rs7804356 DOM 334/507 567/680 0.01 SKAP2 
15 rs8035957 DOM 410/427 562/692 0.06 RASGRP1 
12 rs3764021 DOM 584/258 914/338 0.07 CLEC2D 
10 rs10509540 DOM 405/427 558/689 0.08 VN1R55P/RNLS 
              
1 rs3024505 REC 30/806 29/1213 0.09 IL10 
 
Table 4.1 T1DM-associated SNPs and AD.  Four statistical models were utilized to 
explore the potential association of T1DM-associate SNPs and AD.  Rs7804356 
(SKAP2) was significantly associated with AD using three of these models (p ≤ 0.05).  
 
To explore the potential function of rs7804356, we tested for an association 
between rs7804356 and SKAP2 expression using SNPExpress.  At the transcript 
level, no association was observed between rs7804356 and SKAP2 expression in 
either human brain or peripheral blood monocytes (PBMC). Further analysis 
indicated that rs7804356 is associated with the intensity of several exon-tiling probes, 
however only one association reached statistical significance in both brain and 
PBMCs after accounting for multiple testing.  The intensity of Affymetrix probe set 
ID_3042670 was significantly associated with rs7804356 in both brain and PBMC (p 
= 9.4x10-6 and 4.6x10-4, respectively).  This probe set hybridizes to region of the 
SKAP2 gene corresponding to a 73bp exon that is expressed as part of the Ensembl 
transcript SKAP2-006 (ENST00000487720).  This exon is not included in the major 
SKAP2 isoform, SKAP2-001 (ENST00000345417).  It is noteworthy that the 3’ end 
of this exon contains the SNP rs3801812, which does not underlie the probeset, and 
which is in perfect LD with rs7804356 (r2 = 1.0 in the HapMap CEU population).  The 
two possible alleles of rs3801812 affect the 3’ splice site of this exon and thus 
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exhibit potential to exert strong effects on the alternative splicing of this rare SKAP2 
exon. 
 
 
 
Figure 4.1 rs7804356 is associated with inclusion of a rare SKAP2 exon.  
Individuals carrying the rs7804356_T allele exhibit increased signal corresponding to 
the rare SKAP2 exon (SKAP2-006 exon 4) in both brain and PBMCs.  SKAP2 exon 
inclusion is expressed in units derived from the probe logarithmic intensity (PLIER) 
method. (http://media.affymetrix.com/support/technical/technotes/plier_technote.pdf) 
 
Using conventional PCR we screened for expression of SKAP2 and the rare 
rs7804356-associated SKAP2 exon.  Primers corresponding to SKAP2 exons 2 
(forward) and 8 (reverse) were used to amplify both total SKAP2 and the region 
spanning the rare SKAP2 exon.  Although SKAP2 was detectable in our brain 
samples, skipping of the rare SKAP2-006 isoform exon 4 was not observed (Figure 
5.2).  Thus, rs7804356 may exhibit a valid association with both AD and SKAP2 
splicing or expression, but perhaps via another linked SNP or structural variant given 
undetectable levels of SKAP2-006 exon 4 in human brain. 
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Figure 4.2 SKAP2 Expression in the Cingulate Gyrus.  SKAP2 lacking the novel 
exon (~300bp) was easily visualized in samples from both AD and non-AD brain 
after 30 cycles of conventional PCR.  The rare SKAP2 isoform containing exon 4 
was not detected (~360 bp). 
 
The T2DM-associated SNP rs2237892 is nominally associated with AD 
 
 A total of one-hundred and sixteen associations between SNPs and T2DM 
were reported in the HuGE Navigator database.  These associations represent fifty-
four unlinked SNPs after removing duplicates and filtering for LD (r2 ≥ 0.8).  A total of 
twenty-five of these SNPs or their proxies were present in our AD case-control 
population.  Association testing, consisting of four separate models, was again 
performed using PLINK.  The Cochran-Armitage test for trend suggests that 
rs2237892 (KCNQ1) is significantly associated with AD (p = 0.03).  Using the same 
model, both rs1470579 (IGF2BP2) and rs391300 (SRR) exhibit non-significant 
trends with AD (p ≤ 0.1).  Several other significant associations with AD were 
suggested by using a dominant model, including rs1470579 (IGF2BP2), rs7756992 
(CDKAL1), rs896854 (TP53INP1) and rs1111875 (HHEX) (p ≤ 0.05).  Multiple other 
non-significant trends with AD were also suggested and were not pursued further. 
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CHR SNP ID TEST AFF UNAFF P GENE 
11 rs2237892 TREND 124/1554 143/2359 0.03 KCNQ1 
3 rs1470579 TREND 554/1124 753/1725 0.07 IGF2BP2 
17 rs391300 TREND 650/1038 901/1603 0.10 SRR 
              
9 rs2383208 GENO 31/232/572 37/406/808 0.06 CDKN2* 
6 rs7756992 GENO 70/309/465 102/515/633 0.10 CDKAL1 
              
3 rs1470579 DOM 469/370 636/603 0.04 IGF2BP2 
6 rs7756992 DOM 379/465 617/633 0.05 CDKAL1 
8 rs896854 DOM 591/238 909/299 0.05 TP53INP1 
10 rs1111875 DOM 530/311 842/411 0.05 HHEX 
9 rs2383208 DOM 263/572 443/808 0.06 CDKN2* 
              
11 rs1552224 REC 27/811 24/1226 0.06 ARAP1 
 
Table 4.2 T2DM-associated SNPs and AD. Only rs2237892 (KCNQ1) was 
significantly associated with AD per Cochran-Armitage or genotypic models.  Other 
SNPs trended toward an association with AD, some appearing in more than one 
model (rs1470579, IGF2BP2; rs2383208, CDKN2*; rs7756992, CDKAL1).  
(*members of CDKN2 include CDKN2A, CDKN2B and CDKN2BAS). 
 
Since rs2237892 was overall the most strongly AD-associated SNP of those 
also associated with T2DM, we pursued any association rs2237892 may have with 
KCNQ1 expression or splicing.  Thus, we tested for association between rs2237892 
and KCNQ1 probe intensity in SNPExpress.  No association was observed between 
rs2237892 and KCNQ1 expression at the transcript level in either brain or PBMC.  
Although several significant associations were observed at the exon level, all but 
one appeared to be skewed by the probe intensity of rare homozygotes.  No 
association retained significance after multiple testing. The one association that 
appeared plausible was between rs2237892 and Affymetrix probe set ID_3317399 
(p = 0.01 in brain, p = 0.04 in PBMC).  This probeset localizes to intron 10 of the full-
lenght KCNQ1 transcript, however there is no indication from the literature that intron 
10 is alternatively included.  Furthermore, the effect of the rs2237892 on probe 
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intensity was opposite between the two tissues.  Thus, the association between 
rs2237892 and KCNQ1 was not pursued further.  Identification of proxies to 
rs2237892 and exploration of their functional associations may lead to a better 
understanding of the association between rs2237892, T2DM and AD. 
 
SNPs associated with DM-related traits exhibit little association with AD 
 
 A considerable number of DM-related traits have been evaluated using 
GWAS to better understand the effects of genetic variants on glucose metabolism 
and plasma glucose homeostasis.  Resultantly, multiple SNPs have been associated 
with these traits, including fasting plasma glucose, glycated hemoglobin and 
response to a two-hour oral glucose challenge.  Thus, we have tested for an 
association between these SNPs and AD. 
 There are currently thirteen reported associations between SNPs and fasting 
plasma glucose levels, only four of which (or their proxies) were present in our AD 
case-control population.  Of the four SNPs, rs340874 (PROX1) is associate with AD 
in a recessive model (p = 0.05 using a recessive model).  Regarding glycated 
hemoglobin, associations with sixteen SNPs have been reported.  Of these, we 
tested the six available in our dataset for association with AD.  Although no 
significant association was observed, rs7072268 (HK1) exhibited a trend with AD (p 
≤ 0.1 using a dominant model).  Likewise, of the five SNPs associated with response 
to a two-hour oral glucose challenge, only two were present in our dataset and only 
one, rs2877716 (ADCY5), exhibited any trend with AD (p ≤ 0.1 using a recessive 
model). 
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CHR SNP ID TEST P TRAIT GENE 
1 rs340874 REC 0.05 Fasting Plasma Glucose PROX1 
            
10 rs7072268 DOM 0.10 Glycated Hemoglobin HK1 
            
3 rs2877716 REC 0.06 2hr Glucose Challenge ADCY5 
 
Table 4.3 SNPs associated with DM-related traits and AD.  Four statistical 
models were used to test for association between each SNP associated with either 
(i) fasting plasma glucose, (ii) glycated hemoglobin or (iii) two-hour oral glucose 
challenge response.  No SNP associated with DM-related traits exhibited a trend 
with AD using trend or genotypic models despite association or trend with AD using 
dominant or recessive models. 
 
Discussion 
 
The primary findings of this study are that (i) SNPs associated with DM or 
DM-related traits are largely unassociated with AD in our case-control population, (ii) 
the T1DM-associated SNP rs7804356 (SKAP2) is nominally associated with both 
AD and SKAP2 splicing, (iii) the T2DM-associated SNP rs2237892 (KCNQ1) is 
nominally associated with AD.  Thus, the cumulative results of this exploratory study 
suggest that genetic modulators of diabetes and related traits exhibit little overlap 
with AD risk.  Nonetheless, individual loci associated with both DM and AD may 
provide novel insights into AD pathogenesis if their association with AD can be 
consistently replicated. 
 A critique of both the strengths and weaknesses of our approach lends to a 
better understanding of these largely negative results.  Regarding the strengths of 
our study, we used only the most robust genetic risk factors for DM and related traits 
to test for genetic overlap between DM and AD.  Furthermore, we utilized an AD 
case-control population with well-defined AD diagnosis that has a suitable age range 
to detect genetic modulators of AD risk.  Concurrently, one weakness of our study is 
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the relatively small sample size and lack of replication in an independent, follow-up 
population.  The exploratory nature of this study prevented us from applying 
corrections for multiple testing, such that SNPs with borderline association with AD 
could be identified.  The winner’s curse phenomenon (wherein initial estimates of 
association are often inflated relative to subsequent studies) and the chance that 
several of our results may be false positives highlight the need for further replication 
of these results.  For the time being, the individual, nominal associations observed 
herein are supported to some extent by data suggesting these SNPs (rs7804356 
and rs2237892), or their proxies, have underlying function.  Thus, further 
investigation of association between rs7804356 and rs2237892 with neighboring 
gene expression should provide insight into the biological validity of these 
associations. 
 Of the SNPs tested for their association with AD, rs7804356 is the most 
strongly AD-associated.  Rs7804356 resides within intron 2 of the major isoform of 
SKAP2.  Rs7804356 is also in perfect LD with another SNP, rs3801812, whose 
alleles define the 3’ splice site of a rare SKAP2 exon.  Despite the major allele, 
rs7804356_T, being associated with increased expression of this rare exon we were 
unable to detect the relevant SKAP2 isoform in human brain.  However, it is yet to 
be determined what association the proxies of rs7804356, including rare and 
structural mutations, have with nearby gene expression and/or splicing.  SKAP2 is 
believed to play a role in cell signaling and may also function as a regulator of α-
synuclein activity [394].  Although α-synuclein is predominantly associated with 
Parkinson’s disease and dementia with Lewy bodies, α-synuclein related pathology 
is also observed in the AD brain [395-397].  While the function of α-synuclein is 
unclear, its abundance in the brain, especially within neural presynaptic boutons, 
suggests that its dysregulation may propagate neurodegenerative disease [398-400].  
Thus, the SKAP2 locus as a whole may be more compelling than rs7804356 alone 
when considering a mechanistic role in AD. 
Although T2DM-associated SNPs were generally not associated with AD in 
our case-control population, there was mild indication that the variant rs2237892 is 
associated with AD.  Other variants in KCNQ1 have been associated with long-QT 
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syndrome and atrial fibrillation, but there is little data to support a role for KCNQ1 in 
human brain.  Only one study from the literature suggests that the KCNQ1 locus is 
expressed in mouse brain and plays some role in epilepsy [401].  Although 
expressed sequence tag libraries suggest that KCNQ1 is expressed in human brain, 
there are no data from the literature to confirm this [402]. 
It may be noteworthy that the strongest associations between the KCNQ1 
locus and T2DM have been observed in Asian populations, whereas our AD case-
control population is largely Caucasian [311].  Thus, ethnicity could confound our 
ability to observe a significant association between rs2237892 and AD.  Regarding 
the other T2DM-associated loci, it is noteworthy that their associations with T2DM 
may be driven by underlying, intermediate phenotypes such as obesity.  As such, 
obesity or body mass index were not accounted for in our AD case-control 
population.  Hence, heterogeneity in body composition of our AD population could 
confound the association of T2DM SNPs with AD. 
Another factor that should be considered when interpreting these data 
pertains to the genetic basis for DM-related traits.  Essentially, traits such as fasting 
plasma glucose and glucose tolerance exhibit little genetic overlap with overt DM per 
GWAS [262].  Thus, the physiologic regulation of plasma glucose should not be 
expected to affect AD risk via DM as an intermediate phenotype.  However, there is 
a well-characterized phenomenon of glucose hypometabolism in the brain that 
precedes AD in certain individuals [403].  Furthermore, aerobic glycolysis within the 
CNS of young, non-demented adults is spatially correlated with β-amyloid deposition 
[404].  A more thorough understanding of the physiology and genetics of CNS 
glucose metabolism should help clarify what role, if any, the genetics of peripheral 
glucose metabolism play in AD risk.   
 
Conclusions 
 
In summary, SNPs that are associated with DM and related traits fail to 
demonstrate significant association with late-onset AD.  While several, individual 
exceptions may exist (ie. rs7804356 and rs2237892), the validity of these 
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exploratory associations must be tested per replication in other AD populations.  At 
the present time it is difficult to interpret these results due to lack of replication and 
due to the possible confounding effects of intermediate phenotypes, such as body 
composition, that were not accounted for as covariates in our study population.  
Replication of our results using AD case-control populations with defined body 
composition will ultimately lead to a better understanding of what contribution, if any, 
DM-associated SNPs impart upon AD risk. 
 
Methods 
 
SNP Selection 
 
 The NHGRI Catalogue of GWAS studies was queried via the Human Genome 
(HuGE) Navigator using the search term “diabetes” [307].  Of the seventy-four 
resultant traits, only those pertaining to T1DM, T2DM or the DM-related traits fasting 
plasma glucose, glycated hemoglobin or two-hour glucose challenge were pursued 
further.  Thus, 253 SNP-trait associations were identified in thirty-eight studies 
published between 2007-2011.  Linkage analysis using the SNAP Proxy tool and 
corresponding data from the 1000 genomes project and HapMap project was 
performed [312].  If two or more SNPs exhibited tight linkage disequilibrium (LD, r2 > 
0.8) only the most significantly DM-associated SNP was retained for further analysis.  
Furthermore, if a SNP was no present in our dataset, SNAP Proxy was used to 
select a suitable proxy based on LD (r2 > 0.8). 
 
Sample Population Characteristics and Genotyping 
 
 Recruitment and detailed characteristics of our case-control AD population 
have been reported previously [311, 390].  Briefly, samples data was derived from 
the Mayo Clinic case-control AD series, which consisted of male and female 
individuals between the ages of 65 and 80 years of age.  Probable diagnoses and 
autopsy diagnoses of AD were made according to NINCDS-ADRDA criteria.  Non-
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demented controls were required to have a score of zero on the Clinical Dementia 
rating scale.  Autopsy-selected controls were required to exhibit limited AD-
pathology (Braak<2.5, not including other unrelated pathology). 
 
Association Testing (PLINK) 
  
PLINK was used to perform all AD association testing [313].  Several models 
of association were used, including the Cocrane-Armitage test for trend, a two-
degrees of freedom genotypic model and one degree of freedom dominant and 
recessive models.  Due to the exploratory nature of this study multiple testing was 
not formally addressed; associations were said to be nominal given p < 0.05. 
 
SNPExpress analysis 
 
 The publicly available SNPExpress database, including extended transcript 
and exon dataset brainpbmc006, was used to query tissue-specific associations 
between SNPs that exhibited nominal associations with AD using a trend model 
[354].  Multiple testing was accounted for by applying a Bonferoni correction.   
 
Human Tissue and PCR 
 
 Frozen tissue from the anterior cingulate gyrus of individuals receiving 
diagnoses of AD or age-matched controls was obtained from the Sanders-Brown 
Center on Aging.  These samples have been described in detail elsewhere [316, 
317].  Primers corresponding to SKAP2 were designed using Primer 3.0 software 
[405].  Forward and reverse primers corresponded to SKAP2 exon 1 (5’-CAG CAC 
CTC CTC TCC CTA CC) and exon 5 (5’-GGG GGC TTC ATC GTC TTT AT), 
respectively. Conventional PCR using Platinum Taq (Invitrogen, CA) was performed 
over 30 thermal cycles (95°C for 5 min followed by cycling at 95°C for 30 s, 60°C for 
30s, 72°C for 1 min and a final extension at 72°C for 2 min).  PCR products were 
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separated using 8% TBEPAGE gel electrophoresis and visualized using SYBR-gold 
fluorescent stain (Invitrogen) and a fluorescence imager (FLA-2000, Fuji). 
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CHAPTER FIVE 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
 
Summary of Objectives and Primary Findings 
 
While the sizes of GWAS populations are still increasing, the amount of 
trait/disease variance explained by SNPs at the GWAS level appears to be reaching 
its asymptote.  Thus, I have turned to the intersection of these GWAS to identify 
SNPs which are associated with AD but would not be detected under the strict 
cutoffs of GWAS imposed by multiple testing.  I have applied this avenue of research 
primarily to the study of Alzheimer’s genetics, although the methodology is general 
enough to be applied to any assortment of traits or diseases with a significant 
genetic component. 
The intersection points I have chosen to evaluate with regard to AD are 
plasma cholesterol, rheumatoid arthritis and diabetes mellitus – three traits or 
diseases with significant genetic components and controversial associations with AD.  
As with AD, each of the aforementioned traits or diseases has been subject to 
exhaustive GWAS.  It is noteworthy that the outcome of GWAS typically entails the 
identification of less than one hundred SNPs as being associated with a trait, where 
each SNP exerts a small effect (OR < 2.0) on the trait in question.  The SNPs 
identified in my studies fall within this domain.   
In search of SNPs that are nominally associated with AD and robustly 
associated with related traits or diseases, I devised two central objectives.  The 
primary objective of my work was to identify genetic variants identified by GWAS that 
contribute to both AD and plasma cholesterol, RA or DM.  With regard to this 
objective, I have relied heavily upon the catalogue of published GWAS that is 
maintained by the Office for Population Genomics (a division of the National Human 
Genome Research Institute and the National Institutes of Health).  Variants 
associated with traits of interest were identified via a web-based interface known as 
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the HuGE Navigator.  Testing for an association between these variants and AD has 
led to my primary findings are that (i) cholesterol-associated SNPs, as a group (p < 
0.05), confer significant AD risk whereas RA- and DM-associated SNPs do not and 
(ii) individual SNPs associated with plasma cholesterol, RA or DM are nominally 
associated with AD risk and age of onset (p ≤ 0.05). 
The secondary objective of my work was to investigate the potential 
function(s) of genetic variants shared between disease traits.  This objective was 
intended to characterize novel molecular mechanisms that underlie AD 
pathogenesis.  The bioinformatics of functional genetics remains relatively 
underdeveloped as compared to that of GWAS.  Due to the incredible size and 
complexity of the genome it has proved difficult to predict on a high-throughput scale 
which genetic variants are capable of altering gene expressing and thus phenotype.  
In the course of my work I have utilized the program SNPExpress for hypothesis 
building purposes with regard to SNP-gene expression association.  This program 
capably tests the association between SNPs and exon-tiling array data, however the 
dataset provided with the program is limited to two tissue types and normalization of 
the tiling array data is predefined by the individuals who uploaded it.  That said, 
future developers will hopefully build upon SNPExpress and similar tools to provide 
expanded capabilities for analyzing the association between genetic variants and 
isoform-specific gene expression in multiple cell types. 
From the hypotheses I constructed using SNPExpress, I proceeded to test for 
both in vivo and in vitro associations between SNPs at the interface of AD and 
associated traits in human tissue and relevant cell lines.  To this end, my data 
support a role for rs3846662 in AD risk and HMGCR exon 13 splicing.  It is 
noteworthy that rs3846662 is also associated with the cholesterol-lowering response 
to statins and is an example of how pharmacogenomics may enter into disease 
treatment.  Thus, further study of the HMGCR locus may reveal AD-modifying 
potential with regards to both risk and therapeutic intervention.  Likewise, my data 
support a role for the regulation of BACE2 in both AD and RA.  The AD-associated 
SNP rs2837960 trends with expression of both total BACE2 and the BACE2d7 
isoform in human brain.  Although no clear mechanism exists to explain the 
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association between rs2837960 and BACE2, as linkage disequilibrium maps are 
refined it may be possible to find a proxy to rs2837960 that is predicted to influence 
BACE2 regulation more proximally.  A third example of a potentially functional SNP 
from my data is that of the DM- and AD-associated SNP rs7804356.  The SNP 
rs7804356 appears to be associated with inclusion of a rare SKAP2 exon per my 
analysis of SNPExpress data.  The potential benefits of studying the SKAP2 locus 
with regard to AD pathogenesis are yet to be determined. 
Thus, variants identified by GWAS provide a means for evaluating the genetic 
and molecular intersection between different disease traits.  With respect to effect 
size, the newly AD-associated SNPs described in previous chapters exhibit similar 
odds ratios to SNPs robustly associated with AD. It is possible that the nominal 
associations described within this body of work will be subject to the winners curse, 
ie. that as they are tested in larger sample sizes that the effect size will appear to 
diminish.  That said, (1) loci implicated by these SNPs may still play functional roles 
in AD pathogenesis and (2) the cumulative effect of SNPs with very small effects on 
a trait can be significant, as with the case for human height. 
 
The Sum of Small Effects 
 
In 2008, the journal Nature Genetics published 3 separate GWAS evaluating 
the contribution of SNPs to human height, which is approximated to be 80 percent 
heritable.  In total, these three studies identified 54 SNPs as being associated with 
human height in ~75,000 individuals.  No meta-analysis of the data was provided, 
and each of these three studies failed to explain more than 4 percent of the variance 
in human height [406-409].  The fact that study was relatively underpowered became 
the scapegoat explanation for why such a small fraction of heritability was explained.  
If this was true, then it was a bit surprising when a study of nearly 300k SNPs in only 
~4,000 individuals appeared to explain a significant proportion of variability in height 
when SNPs with even very small effects were included – i.e. that SNPs are capable 
of explaining 45 percent of the variance in human height [410].  The cumulative SNP 
effect described by Yang J et al. did not belabor the contribution of individual SNPs 
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to human height, but suggests that SNPs with very small effects, in large quantities, 
can explain a significant amount of variance in a heritable trait. 
Thus, the nominal associations between SNPs and AD uncovered at the 
interface between AD and cholesterol, RA or DM should not be taken lightly.  This is 
especially true in light of data suggesting that several of these variants affect the 
regulation of nearby genes.  Further application of the method I have utilized for my 
studies to the investigation of SNPs at the interface of multiple traits will likely 
uncover a multitude of variants with nominal associations and small effect sizes.  
Hence, the intersection of GWAS for multiple associated traits may yet be proven to 
contain variants that highlight novel pathways underlying common diseases.  The 
two factors that limit the usefulness of this approach, namely the lack of rare variants 
included in GWAS and the inability to predict the function of these variants, will likely 
be ameliorated as technology progresses.  Hence, I turn the focus of my discussion 
to emerging trends in genetic research and their potential to uncover the missing 
heritability of genetic disease. 
 
Reproducibility of GWAS Findings 
 
 One issue that must be addressed regarding the methods presented here, as 
with all GWAS, is the reproducibility of results.  Aside from the APOE locus, which 
exerts a relatively large effect on AD risk, initial AD GWAS at times struggled to 
report consistent associations between studies.  Likewise, this phenomenon plagues 
the study of virtually all GWAS.  Although the work presented in previous chapters 
has employed a small replication populations to assess the validity of these findings 
it is essential that replication in much larger populations confirm these data.  Diligent 
replication and meta-analysis has successfully and unequivocally identified the 
association of novel loci with many traits and conditions.  Notwithstanding, other loci 
have failed replication and thus fallen between the cracks of GWAS.  Several 
common factors could account for this lack of reproducibility.   
 The first of these factors consists of the rigorous and perhaps overzealous 
correction of statistical data for multiple testing.  As an example, two early AD 
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GWAS reported new associations between AD and the loci CLU, PICALM and CR1.  
Although CLU was heralded in both studies as being associated with AD, PICALM 
and CR1 only meet the required cutoff of statistical significance for association with 
AD in their respective studies [109, 411].  When the respective investigators 
reanalyzed their data both groups observed highly significant associations of 
PICALM and CR1 in their datasets that simply did not meet their initial cutoffs.  
Granted, all three of these loci have now been highly replicated and are confidently 
associated with AD despite the failure of initial studies to appreciate the contribution 
of all three loci.  From this example it is clear that rigorous replication and meta-
analysis can overcome the imposition of multiple testing corrections.   It remains 
noteworthy that the statistics-heavy methods of association studies will make it 
difficult to separate the proverbial wheat from the chaff.  One possible avenue to 
circumvent this problem would be a return to family based linkage analysis, which 
benefits from a more homogenous genetic background and potentially less noise.  
While neither method is perfect, emerging genomic sequencing technologies make 
both methods attractive. 
A second factor that affects the reproducibility of GWAS data is that of 
inaccurate phenotype characterization.  As expected, the phenotypes of complex 
genetic disease are themselves multifaceted and thus diagnosis is at times 
inaccurate.  For example, the clinical diagnosis of AD per NINCDS-ADRDA criteria 
has exhibits a sensitivity between 65-96% while the specificity ranges from 23-88% 
[412].  Even neuropathologic diagnosis of AD, the gold standard of the field, is 
plagued by mixed and often confounding CNS pathology.  Thus, virtually no AD 
GWAS of sufficient size is composed strictly of pure AD cases.  Likewise, the 
selection of controls can be inconsistent depending on recruitment center and 
inclusion/exclusion criteria.  The use of young control subjects may be especially 
detrimental if appropriate time is not allowed for follow-up since these individuals 
may convert to AD or develop CNS pathology that would result in exclusion from the 
study or classification as AD itself. 
To eliminate the confounding effects of inaccurate diagnosis or inappropriate 
control selection there has been a move toward the use of quantitative traits for 
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GWAS rather than disease status.  One immediate benefit is the applicability of 
linear, rather than logistic regression, for association testing with covariates since 
quantitative traits are continuous and often linear as compared to the binomial, 
categorical nature of disease status.  Another benefit involves increased inter-
observer agreeability, and thus consistency between centers participating in GWAS.  
However, no science is perfect and measurements as straightforward as those of 
plasma cholesterol can vary between centers due to differences in sample collection 
method and handling as well as the instruments used for analysis.  These inter-
observer differences in quantitative traits may be ameliorated or confounded by 
emerging technology and will undoubtedly be subject to consensus panels and 
standardized protocols.  Regardless, valuable underlying biological insights will likely 
be gleaned from GWAS of quantitative traits, such as longitudinal hippocampal 
atrophy, PIB binding and measurements of CSF tau and β-amyloid with regard to AD.  
Our understanding of the pathobiology of other disease conditions will undoubtedly 
benefit from similar endeavors. 
A third factor which clouds the reproducibility of GWAS data is that of ethnic 
heterogeneity and population substructure.  Given that new and ancestral alleles 
parse differently among different ethnic populations, it should not be a surprise that 
heritable traits may be differentially regulated in different ethnicities.  In other words, 
a similar disease phenotype may be modulated by different alleles in different 
populations.  Unfortunately, the majority of GWAS to date have been performed 
using largely Caucasian populations.  While GWAS utilizing Caucasian populations 
have provided insight into novel mechanisms underlying complex genetic disease, 
ethnicity-specific mechanisms of disease likely remain underappreciated.  Likewise, 
GWAS data from population admixtures will be somewhat confounded by the 
heterogeneous genetic background from which they are derived.  Although smaller, 
better-characterized populations have been used for GWAS, the number of these 
studies remains relatively small.  And since statistical power is driven by large 
sample sizes, the allure of meta-analysis of heterogeneous populations continues to 
confound GWAS.   
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A fourth consideration is that the reproducibility of GWAS will be consistently 
challenged by the relatively small effect sizes of most genetic variants.  Hence, the 
use of large sample sizes is unavoidable per the basis of the common-disease, 
common-variant hypothesis since any variant with a large detrimental effect would 
likely have been removed from a population by selective pressure.  Emerging 
genomic technologies have provided insight into the number of so-called common 
variants with minor allele frequencies > 5% as well as the number of more rare 
variants.  These rare variants (minor allele frequency of ≤ 1%) are now being 
heralded as a potential reservoir of missing heritability capable of exerting relatively 
larger effects on disease.  As sequencing techniques gain traction, becoming more 
accessible and less expensive, it will be possible to include rare and structural 
variants in GWAS.  Hence, the combination of common and rare variants with mixed 
effect sizes may allow for a more complete explanation of the heritability of human 
conditions.  Nonetheless, so long as the association study method is used the 
requirement for large study populations will remain.  At the same time, correction for 
genetic heterogeneity and population substructure may be feasible and allow for 
more precise analysis of association data. 
Yet a fifth factor to consider is that of environmentally sensitive intermediate 
phenotypes.  A classic example of this phenomenon is that of the FTO locus that 
has been associated inconsistently with T2DM.  Underlying this inconsistency is the 
more robust association of FTO with obesity, which itself is strongly associated with 
the risk of T2DM.  Thus, GWAS of T2DM that used a predominantly obese T2DM 
case selection were likely to identify FTO as a risk locus.  It is noteworthy that while 
a T2DM GWAS using non-obese individuals will not display an association with the 
FTO locus, this locus in fact remains a risk factor for diabetes via its influence on an 
intermediate phenotype, ie. obesity, that greatly increases risk predilection.  
Examples in AD GWAS may prove to include loci affecting the efflux of clearance of 
β-amyloid from the CNS via the blood brain barrier, but may only take effect in 
individuals with co-morbid cerebrovascular disease. 
Thus, finding reproducible associations between human traits or diseases and 
genetic variants will remain challenging.  Assuming that reproducibility will remain a 
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significant issue in association studies there will likely be a move toward the 
characterization of functional variants, as was undertaken in my research, for the 
sake of identifying biologically relevant associations.  The identification of functional 
variants will not only facilitate the verification of GWAS data but will hopefully 
advance the identification of relevant disease mechanisms and therapeutic targets. 
GWAS has already provided novel insights into human biology, being equated with 
random mutagenesis at the human scale, and will continue to do so[4].  The rate of 
these discoveries will hopefully be accelerated as our view of the human genome 
evolves. 
 
The Genome as We Know It 
 
 Since the draft released in 2001, significant effort has been poured into 
refining the sequence of the human genome.  To this end, multiple projects have 
been launched with the intention to capture individual human genomes.  At least two 
such projects have managed to sequence in near entirety the diploid genome 
sequences of Craig Venter and James Watson using separate techniques[13, 413].  
Along with other efforts, such as the sequencing of individuals for structural variation, 
these projects have revealed how much was overlooked when the consensus 
human genome was released in 2004 [414]. 
 So what is known of the assortment and volume of human variation now ten 
years after the draft genome release?  Out of the ~3.2 billion base pairs that we 
humans count on to direct our innate cellular activity and homeostatic responses to 
the surrounding environment, ~3 million are confirmed SNPs.  Furthermore, each 
individual also carries another ~1 million indels (medium sized insertions and 
deletions) that account for ~78% of the variant bases in the human genome [13].  
Astoundingly, each individual is also believed to carry ≥250 loss of function 
mutations among our ~22,000 genes.  With regard to population-level variation, the 
pilot of the 1,000 Genomes Project has cumulatively identified ~15 million SNPs, ~1 
million indels and another ~20,000 structural variants across seven different ethnic 
groups [14].  Atop all of this variation, data also suggest that we accumulate single-
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base mutations at a rate of 10-8 substitutions per base pair with each successive 
generation (which equates to ~0.02% of the genome).  
 Perhaps beyond the scope of this discussion, another point worth mentioning 
is the amount of variation that exists within the transcriptome (ie. the summation of 
transcribed RNA sequences).  One important consideration is that for the majority of 
our ~22,000 genes we likely have multiple alternatively spliced transcripts.  Between 
60-90% of our genes are expressed as more than one isoform, with an average of 
2.75 alternatively spliced transcripts per gene [415].  The functional significance of 
these events has been questioned and may to some extent reflect stochastic noise 
in the alternative splicing process [416].  At the very least, ~20 of these splicing 
events are (1) involved in the generation of functional proteins based on sequence 
conservation between multiple species  and (2) influenced by human variation in a 
tissue-specific manner [354, 417, 418]. 
 Considering the size and variation of the human genome it is reasonable to 
ask what proportion of our DNA has meaningful function.  To this end it is 
noteworthy that a large portion of non-coding DNA sequence is highly conserved.  
Approximately 6% of the human genome has been subject to selective pressure 
over the past 100 million years, 75% of which is non-coding sequence.  This is 
particularly interesting because of recent data that suggest this non-coding 
sequence participates in regulating developmentally-specific events [419].  We also 
now know that a portion of this non-coding sequence is transcribed as regulatory 
micro RNAs (miRNA, which act largely to silence gene expression), PIWI-interacting 
RNAs (capable of repressing transposon activity) and large intergenic non-coding 
RNA (lincRNA, the function of which is unclear).  The phenomenon of ubiquitous 
transcription, or the segmental expression of virtually the entire genome at low levels, 
suggests that, like alternative splicing, some portion of non-coding transcription is no 
more than noise [420].  Cumulatively, these events will make it difficult to rule out 
meaningful regulation of the genome in light of so much variation.  With regard to the 
functional capacity of our genome to manifest human phenotype and disease risk we 
will also have to develop a better understanding of the epigenomic changes 
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associated with aging and environmental exposure as well as the long-range 
interactions within the genome. 
  
Toward a Greater Understanding of Heritability 
 
Although SNP-based GWAS has proved to be an invaluable technique for 
discovering novel associations between loci and different traits or diseases, it 
appears to have reached an asymptote with regard to explaining human heritability.  
This may be in part due to the difficulty involved in recruiting sufficiently large, 
homogenous study populations but likely suffers from the exclusion of low-frequency 
variants and structural mutations.  Emerging sequencing technologies will one day 
overtake the place of array-based genotyping platforms, allowing for greater 
coverage of genetic variation.  This increase in coverage will likely prove useful to 
GWAS by enhancing the resolution of LD maps.  These expanded LD maps should 
also allow for more thorough principal component analysis and correction of 
underlying population substructure. 
GWAS is not the only method that will benefit from the expanded coverage 
provided by whole-genome sequencing.  A return to family-based linkage analysis, 
equipped with high-resolution sequence, will provide a parallel avenue for the study 
of heritable disease.  Data derived from linkage studies will share the a priori benefit 
of GWAS but should be less noisy as a result of being derived from a more 
homogenous genetic background.  Linkage analysis will also provide greater ability 
to infer interactions between variants as well as a means of studying the effects of 
newly introduced variants across generations.  Since sample sizes will be 
significantly smaller than those of GWAS they will theoretically be easier to identify, 
however any pathways or targets identified may be specific to the pedigrees being 
studied.  Thus, the extrapolation of knowledge gained from whole-genome 
sequencing and linkage-based studies may prove to be difficult.  Regardless, the 
identification of novel disease pathways will provide additional insight into disease 
pathogenesis and aid in identification of therapeutic targets. 
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 The exact methods of whole-genome sequencing using emerging 
technologies are still being worked out, and will have to evolve along with technology.  
The 1,000 Genomes Project gives some insight into the benefits of high-coverage, 
low-coverage and exome (exon-only) sequencing.  Family based linkage studies, 
predicted to be relatively small, will benefit most from high-resolution sequencing, 
while population-based GWAS will likely benefit more from high-throughput, low-
resolution sequencing.  Granted, as the cost and time required to perform high-
resolution sequencing are reduced even GWAS will likely move toward these 
platforms.  In either case, there will be extraordinary demand for computational tools 
that facilitate data storage, visualization and analysis.  Anecdotally, all researchers 
stand to benefit from centralized computational platforms designed for the study of 
genetic data.  Computation should also aim to include experimentally derived 
algorithms that facilitate functional predictions based on primary sequence data.  To 
this end, the ENCODE project has already made multiple advances in the field, 
however it must continue to evolve as the tissue and environment-specific structure 
of the genome increase in complexity. 
 
Personalized Genomic Medicine 
 
 There is tremendous potential for clinicians and patients both to benefit from a 
more complete understanding the genetic basis of heritable disease.  At the basic 
science level there is much work yet to be done in identifying, replicating and 
validating causal genetic variants.  Meanwhile, healthcare systems will have to 
facilitate the translation of genomic information into the clinical arena.  The assembly 
of teams that are cost effective in generating and analyzing genomic patient data 
may be difficult, but so will be gaining the trust and acceptance of the patient 
community.  Thus, an extraordinary amount of inter-professional cooperation will be 
necessary to realize the potential of personalized genomic medicine (PGM). 
 The benefits of PGM are essentially two-fold.  The first benefit to be realized 
clinically will likely be the development and use of therapeutics whose targets were 
identified as loci that are affected by genetic variants.  Decisions regarding the 
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choice and dosing of certain drugs are likely to be influenced by genetic information 
as our understanding of pharmacogenomics grows (ie. warfarin).  Furthermore, 
expanded use of conventional therapeutics for the treatment and prevention of 
conditions not currently recognized by the FDA will likely be realized.  Granted, both 
of these approaches will require lengthy clinical trials and may be outpaced by the 
second benefit of PGM, the use of genomic data to evaluate disease risk and 
prognosis.   
Inclusion of genomic information in clinical decision making currently shows 
little added utility beyond the evaluation of classical risk factors, but does appear to 
be consistent with disease risk [421].  Perhaps not within the boundaries of PGM, 
clinical genetic testing is already mandatory for newborns in most of the United 
States.  Basic and clinical science, predating the GWAS era, has proven that genetic 
testing for inborn errors of metabolism can drastically improve health outcomes.  It is 
only a matter of time before computational biology allows for risk assessment, 
counseling and treatment of more complex genetic disorders. 
 Lastly, no discussion of PGM would be complete without mention of the 
ethical considerations behind public use of genetic data.  The protection of 
individuals, whether research participants or patients, is of ultimate importance.  
Disseminating personal genomic information entails both benefits and risks.  It has 
been debated whether the knowledge of one’s genetic risk for disease is stress 
inducing and detrimental to an individual’s health.  It seems that the diagnostic 
accuracy of the genetic risk factor comes into play, as well as the severity of the 
disease (eg, having increased risk for late-onset AD vs. certain diagnosis of 
Huntington’s disease).  Beyond the hands of the individual to whom genomic data 
belongs are other societal and legal issues.  Fear of discrimination, based on 
ethnicity or disease risk, as well as increased insurance premiums for at-risk 
individuals are of concern.  These ethical issues must be publicly addressed and 
legally solved prior to the integration of PGM into health care at large. 
 In summary, this is an exciting time for genomic and genetic research.  
Multiple avenues are opening to facilitate this research, enabled by new and cost-
effective technologies.  Although the majority of human heritability remains to be 
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explained, great progress has been made that lays the foundation for advancing our 
ability to catalogue variance in human traits and diseases.  Even within a few short 
years the scientific community will find itself in possession of an eruption of genetic 
data it has not seen before.  Informatics and computational biology will have to race 
to keep up with the volume of genomic and genetic data being generated and 
clinicians must prepare themselves to facilitate integration of this information into 
health care.  Society as a whole will be subject to the spurs of an emerging genomic 
era, and all members will be responsible for the responsible development and 
implementation of the knowledge we receive. 
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